

Vale of York CCG Medicines Commissioning Position - Published Version 42 (November 2017).

For further advice on commissioning of individual drugs contact VOYCCG.Rxline@nhs.net	.
Key	Status
Red	Hospital specialist prescribing only (other specialist use will be stated)
Amber - shared care	As for Amber, but suitable for continuation by a GP within written and agreed shared care frameworks, and according to the agreed process for transfer of care of those drugs
Amber	Requires initiation or recommendation by a specified member of the Hospital Specialist Team. Suitable for continuation by a GP, with appropriate supporting documents. No written shared care agreement necessary
Green	May be initiated and continued in primary care
Grey	No formal commissioning position at the current time, do not use.
Black	Not routinely commissioned, do not use

Drug	Indication	Classification	Comment
Abasaglar® - Biosimilar Glargine insulin	Treatment of diabetes mellitus	Amber - specialist initiation	for new patients only. To be prescribed by brand. As per NICE guidance January 2016 - MCC
Abatacept	RA	Red	
Abiraterone	Metastatic prostate cancer	Red	NICE TA259 - Prostate cancer (metastatic, castration resistant). Red where funding supported by NHS England, refer to Cancer Drugs Fund
Abiraterone	Treatment of metastatic hormone-relapsed prostate cancer before chemotherapy is indicated	Red	May 2016 MCC - NHSE funded
Acamprosate	Alcohol dependence	Amber - shared care	If prescribed in conjunction with alcohol misuse service. Otherwise it is RED
Accrete D3®	Calcium & vitamin D supplementation	Green	See medal ranking for CCG choices.
Acetylcysteine	Idiopathic pulmonary fibrosis (unlicensed)	Amber - shared care	
Acitretin	Psoriasis	Red	Specifically designated as "hospital only" by product licence or by DH/NICE
Acrivastine (oral antihistamine)	Hayfever & allergic rhinitis	Grey	Ratified following MCC February 2015. Refer to Vale of York CCG medal rankings for hayfever & allergic rhinitis formulary choices http://www.valeofyorkccg.nhs.uk/rss/index.php?id=medal-ranked-drugs
Actonal combi® (risedronate with calcium & vitamin D)	Osteoporosis	Black	May 2017 MCC
Adalimumab	Licensed indication including RA approved by NICE	Red	Commissioned in accordance with relevant NICE guidance. Not for GP prescribing.
Adalimumab	for treating non-infectious uveitis	Red	Aug 2017 MCC
Adalimumab	plaque psoriasis in children and young people	Red	Aug 2017 MCC
Adcal D3® formulations	Calcium & vitamin D supplementation	Green	See medal ranking guidance for CCG choices.
Adefovir	Hepatitis B	Amber - shared care	
Aflibercept (Eylea®)	Age related macular degeneration & diabetic macular oedema	Red	August 2015 MCC - Approved in line with NICE TA 346.
Aflibercept	for treating visual impairment caused by macular oedema after branch retinal vein occlusion	Red	Oct 2016 MCC - In line with NICE TA 409
Aflibercept	Cancer	Red	Where funding supported by NHS England, refer to Cancer Drugs Fund
Agalsidase	Fabry's disease	Red	Subject to NHS England commissioning policies
Agomelatine (Valdoxan®)	Major depression	Red	Ratified following February 2015 MCC. Restricted to treatment of resistant cases e.g. after 3 other antidepressants have failed.
Aldesleukin	Cancer	Black	As per NHS England position
Alendronic acid/alendronate	Osteoporosis	Green	See medal ranking for CCG choices http://www.valeofyorkccg.nhs.uk/rss/data/uploads/prescribing/medal-ranked-drugs/medal-ranking-oral-bisphosphonates-voyccg-march-2015.pdf
Alfentanil spray 5mg/5mL	All indications	Red	June 2017 MCC
Alfentanil injection	Palliative care	Amber - specialist recommendation	April 2016 MCC - Confirmation of formulary status
Algesal	OA	Green	
Alirocumab	primary hypercholesterolaemia or mixed dyslipidaemia.	Red	Oct 2016 MCC - In line with NICE TA393 - lipid specialist initiation and prescribing
Alimemazine	All indications	Black	June 2017 MCC
Aliskiren	Hypertension	Green	
Alitretinoin	Severe chronic hand eczema	Red	Specifically designated as "hospital only" by product licence or by DH/NICE

Alogliptin (Vipidia®)	Type 2 diabetes	Green	Dec 15 MCC - Recommended as 1st line within its class when used within its license as per NICE guidance.
Alprostadil intracavernous injection (Caverject®)	Erectile dysfunction	Green	Approved following Oct 15 MCC as per CCG RSS guidance
Alprostadil urethral sticks (Muse®)	Erectile dysfunction	Green	Approved following Oct 15 MCC as per CCG RSS guidance
Alprostadil 3 mg/g cream (Vitaros®)	Erectile dysfunction	Green	Approved following Sept 15 MCC - as per CCG RSS guidance
Amantadine HCl (Symmetrel®)	Parkinson's disease	Amber - specialist recommendation	August 2017 MCC - Conformation of commissioning position
Ambrisentan	Pulmonary hypertension	Red	NHS England commissioned specialist centres only
Amifampridine	Symptomatic treatment of Lambert-Eaton Myasthenic Syndrome	Black	http://www.england.nhs.uk/wp-content/uploads/2013/04/d04-ps-a.pdf
Amikacin	All indications	Red	June 2017 MCC
Amitriptyline	Licensed indications e.g. nocturnal enuresis and off label indications e.g. neuropathic pain, IBS.	Green	Amitriptyline is the preferred agent where either amitriptyline or nortriptyline is recommended as an option.
Amiodarone	Anti-arrhythmic - atrial fibrillation	Amber - shared care	
Amisulpride	Schizophrenia	Amber - shared care	http://www.lhp.leedsth.nhs.uk/common/guidelines/detail.aspx?id=612
Amphotericin	Antifungal	Red	
Anagrelide	Thrombocythaemia	Red	
Anakinra	Adult indications	Black	As per NHS England commissioning position
Anastrozole	Breast cancer	Amber - specialist recommendation	Prescribe generically
Antazoline sulfate 0.5%, xylometazoline hydrochloride 0.05% (Otrivine-Antistin®)	Hayfever & allergic rhinitis	Green	Ratified following MCC February 2015. Refer to Vale of York CCG medal rankings for hayfever & allergic rhinitis formulary choices http://www.valeofyorkccg.nhs.uk/rss/index.php?id=medal-ranked-drugs
Antimalarials	Malaria prophylaxis	Black	Where appropriate, prescribing will be undertaken on a private basis -national policy
Antituberculosis (TB drugs)	Treatment of tuberculosis	Red	National guidance indicates TB should be treated in specialist clinics where drug treatment is provided free of charge to the individual
Antox (previously Bio-antox)	Pancreatitis	Red	
Apixaban (Eliquis®)	Prevention of VTE after total hip/knee replacement	Red	NICE TA 245 - prevention of VTE after total hip and knee replacement
	Thrombo-prophylaxis in adult out-patients (>16yrs) with non-surgical lower limb immobilisation	Red	Refer to joint York & Scarborough/CCG communication which indicates that patients who are unable to self-administer low molecular weight heparin as a subcutaneous injection will be offered alternative treatment options. If this is apixaban, the consultant will prescribe the full course of apixaban which will be supplied by the hospital.
	Stroke prevention in AF	Green	Refer to CCG AF pathway and GP decision aid
	Treatment and secondary prevention of DVT/PE	Green	June 2015 MCC - Approved in line with NICE TA 341
	Pre and post cardioversion	Red	Approved as a treatment option when indicated for patients planned to receive elective cardioversion
Apomorphine	Parkinsons Disease	Amber - shared care	Approved in line with NICE TA 341
Apremilast (Otezla®)	Adults with moderate to severe chronic plaque psoriasis	Red	Feb 17 MCC - Changed from Black to RED
Apremilast	active psoriatic arthritis.	Red	March 2017 MCC - In accordance with NICE guidance
Aprepitant "Emend"	All indications	Red	June 2017 MCC
Aproderm	Creams/Gels for everyday use, frequent application.	Green - Third line after Epimax	April 2016 MCC - See Emollient Medal Ranking
Aquadecks	Multivitamin for brain health	Black	Not licensed and no recommendation from National Advisory Committee for Borderline Substances . CCG policy in development
Aqua Max wash	Gel/Washes/Soap substitute	Black	April 2016 MCC - See Emollient Medal Ranking
Aquamax Cream	Creams/Gels for everyday use, frequent application.	Green - First line	April 2016 MCC - See Emollient Medal Ranking
Aqueous Cream	Gel/Washes/ Soap substitute	Black	April 2016 MCC - See Emollient Medal Ranking
Arachis oil enema	Faecal softener	Green	April 2016 MCC - Confirmation of formulary status
Aripiprazole oral	Schizophrenia	Amber - shared care	http://www.lhp.leedsth.nhs.uk/common/guidelines/detail.aspx?id=864
Aripiprazole depot injection	Schizophrenia	Grey	Refer to VOYCCG.Rxline@nhs.net
Armour thyroid	Hypothyroidism	Black	Inherited policy - NYYPCT
Asthma drugs for Management in Primary Care (see link to pathway)	Asthma	Green	Management of Asthma in Primary Care Pathway MCC April 2017
Atomoxetine	ADHD	Amber - shared care	Prescribing in adults permitted providing included in shared care guideline
Atorvastatin	Lipid lowering	Green - 1st line	change in the order of choice of statin on the formulary so that atorvastatin would move from 2nd line to 1st line in line with NICE guidance and simvastatin would move from 1st to 2nd line
Atropine sulphate eye drops 1%		Green	
Auranofin (oral Gold)	Immunosuppression	Amber - shared care	Shared care for the indications listed in the guideline only
Autologous serum ('Special')	Last line treatment for severe dry eye, exposure keratitis and neurotrophic keratitis	Red	May 2016 MCC
Avanafil (Spedra®)	Erectile dysfunction - adult men	Green	But refer to CCG medal ranking guidance
Aveeno Bath and Shower Oil	Bath oil / additives	Black	April 2016 MCC - See Emollient Medal Ranking
Aveeno cream	Creams/Gels for everyday use, frequent application.	Black	April 2016 MCC - See Emollient Medal Ranking
Aviticol 20 000 iu caps	Vitamin D for deficiency	Green	Feb 16 MCC Second Line Option - See Oral Vit D Medal Ranking

Axitinib	Cancer	Black	If commissioned by NHS England (e.g. Cancer drugs fund) hospital specialist prescribing only
Azathioprine	Includes rheumatoid arthritis, connective tissue disease, vasculitis, Crohn's disease and ulcerative colitis, autoimmune conditions as listed in the SCG	Amber - shared care	Cancer indications are RED - hospital only. Indications are Amber if listed in shared care guideline
Azelastine eye drops	Hayfever & allergic rhinitis	Grey	Ratified following MCC February 2015. Refer to Vale of York CCG medal rankings for hayfever & allergic rhinitis formulary choices http://www.valeofyorkccg.nhs.uk/rss/index.php?id=medal-ranked-drugs
Azithromycin (oral)	Posterior blepharitis	Green	June 2016 MCC - Preferred antibiotic when oral antibiotic treatment required
Aztreonam	Cystic fibrosis	Amber - shared care	As per NHS England policies
BCG vaccine	Travel	Black	Should be prescribed on a private basis as per national policy
Balneum Bath Oil	Bath oil / additives	Black	April 2016 MCC - See Emollient Medal Ranking
Balneum Plus cream	Urea containing Preparations	Green - Second line after Flexitol 10% Urea Crm	April 2016 MCC - See Emollient Medal Ranking
Baricitinib	moderate to severe rheumatoid arthritis	Red	Sept 2017 MCC
Basiliximab	Renal transplant	Red	
Beclometasone 50 microgram nasal spray	Hayfever & allergic rhinitis	Green	Ratified following MCC February 2015. Refer to Vale of York CCG medal rankings for hayfever & allergic rhinitis formulary choices http://www.valeofyorkccg.nhs.uk/rss/index.php?id=medal-ranked-drugs
Bedaquiline (Sirturo®)	Drug resistant tuberculosis	Red	Following MCC August 2015 - Update of NHS England positions - not for GP prescribing.
Bendamustine	Cancer	Red	
Betaine	Homocystinurea	Red	Subject to NHS England commissioning policies
Betametasone (betnovate) (potent) 0.1% cream, ointment 30g, 100g, scalp lotion 100ml	Topical steroid	Green	
Betamethasone/Calcipotriol (Dovobet) ointment 60g, 120g	Topical steroid	Green	
Bevacizumab	Cancer	Red	NICE TA 263- Negative appraisal. Refer to Cancer Drugs Fund. Any prescribing supported by NHS England will be prescribed by the specialist
Biclutamide	Prostate cancer	Amber - specialist initiation	
Bimatoprost PF eye drops	Glaucoma	Amber - specialist recommendation	August 2017 MCC
Bivalirudin	Anticoagulant in adult patients undergoing percutaneous coronary intervention (PCI)	Red	NICE TA 230 Bivalirudin – recommended as a possible treatment for adults with STEMI having percutaneous coronary intervention.
Blinatumomab	previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia	Red	July 2017 MCC - NHSE commissioned
Boceprevir	Hepatitis C	Red	
Bortezomib	Cancer	Red	Subject to NICE guidance and refer to Cancer Drugs Fund. Any prescribing supported by NHS England will be prescribed by the specialist.
Bosentan	Pulmonary hypertension, digital ulceration in systemic sclerosis	Red	Should not be prescribed in primary care for any indication, refer to NHS England commissioning policies. Updated following MCC August 2015.
Bosentan	Digital ulcers	Black	Subject to NHS England commissioning policies
Bosutinib	Cancer - haematology	Red	Refer to Cancer Drugs Fund. Any prescribing supported by NHS England will be prescribed by the specialist.
Botulinum Toxin type A	AOB, hyperhidrosis, migraine, spasmodic torticollis, anal fissures	Red	As per commissioner policies and/or NICE
Botulinum Toxin type A	temporary improvement in facial lines when the severity of these lines has an important psychological impact for the patient	Black	March 2017 MCC.
Bowel cleansing agents e.g. Citramag	Resistant constipation	Green	April 2016 MCC - Confirmation of formulary status
Brentuximab	Cancer	Red	Refer to Cancer Drugs Fund. Any prescribing supported by NHS England will be prescribed by the specialist.
Brentuximab vedotin	CD30-positive Hodgkin lymphoma	Red	July 2017 MCC - NHSE commissioned
Brimonidine (Mirvaso®) gel	Facial erythema of rosacea in adults	Black	Nov-14
Brinzolamide & brimonidine combination eye drops (Simbrinza®)	Ocular hypertension	Black	January 15 MCC recommendation. Single separate eye drop preparations are available for use. Brinzolamide has recently patent expired therefore primary care costs expected to fall over coming months.
Brinzolamide eye drops	Glaucoma	Amber - specialist recommendation	Aug 2017 MCC - Second line Carbonic anhydrase inhibitor
Brivaracetam	Epilepsy	Black	August 2016 MCC - but may be considered on an individual patient basis via prior approval by Chair's action on request by secondary care specialist
Budesonide aqueous nasal spray	Hayfever & allergic rhinitis	Green	Ratified following MCC February 2015. Refer to Vale of York CCG medal rankings for hayfever & allergic rhinitis formulary choices http://www.valeofyorkccg.nhs.uk/rss/index.php?id=medal-ranked-drugs
Buprenorph/Naloxone S/L tabs S/F 8mg/2mg	Opiate dependence	Green	May 2017 MCC Must be prescribed in conjunction with substance misuse service recovery co-ordinator

Buprenorphine 2mg,4mg,8mg s/l tabs	Opiate dependance	Green	May 2017 MCC Must be prescribed in conjunction with substance misuse service recovery co-ordinator
Buprenorphine 7 day patches - Butec®	Treatment of non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia	Green	Sept 2016 MCC - Butec® was the agreed choice of branded generic for use across Y&S when 7 day buprenorphine patches were to be prescribed following WHO pain ladder.
Busulfan	Cancer - haematology	Red	
C1 esterase inhibitors	Hereditary angioedema	Red	Subject to NHS England commissioning policies
Cabazitaxel	Hormone-relapsed metastatic prostate cancer treated with docetaxel	Red	June 2016 MCC - TA 391: for hormone-relapsed metastatic prostate cancer treated with docetaxel
Cabazitaxel	Cancer	Red	Refer to Cancer Drugs Fund. Any prescribing supported by NHS England will be prescribed by the specialist
Cabergoline	Parkinson's Disease; suppress lactation and hyper-prolactinaemia	Amber - specialist recommendation	April 2016 MCC - Confirmation of formulary status
Cabozantinib	previously treated advanced renal cell carcinoma	Red	Sep 2017 MCC
Cacit D3® granules	Calcium & vitamin D supplementation	Green	See medal ranking guidance for CCG choices.
Calceos®	Calcium & vitamin D supplementation	Green	See medal ranking guidance for CCG choices.
Calcichew D3 forte®	Calcium & vitamin D supplementation	Green	See medal ranking guidance for CCG choices.
Calcichew D3® CAPSULES	Calcium & vitamin D supplementation	Green	See medal ranking guidance for CCG choices.
Calcichew-D3 1000mg/800 IU once daily® chew tablets	Calcium & vitamin D supplementation	Green	See medal ranking guidance for CCG choices.
Calcichew D3® chew tabs	Calcium & vitamin D supplementation	Grey	See medal ranking guidance for CCG choices.
Calfovit D3® powder	Calcium & vitamin D supplementation	Green	See medal ranking guidance for CCG choices.
Calmurid cream	Urea containing Preparations	Green - Third line after Flexitol10%Urea Crm	April 2016 MCC - See Emollient Medal Ranking
Canagliflozin	Oral therapy for Type 2 diabetes	Green	June 2016 MCC - As an option as monotherapies for treating type 2 diabetes as per NICE guidance TA390
Canakinumab	Gout	Black	
Caphosol	Adjunct to radiotherapy for the management of radiation induced mucositis	Red	July 2016 MCC - To be provided by acute trust as part of radiotherapy treatment regime if required
Capsaicin (patch)	Neuropathic pain	Grey	
Capsacin cream	postherpatic neuralgia and diabetic neuropathy	Green	as per NICE guidance for neuropathic pain. April 2016 MCC
Capecitabine	Cancer	Red	
Carbimazole	Hyperthyroidism	Green	April 2016 MCC - Confirmation of formulary status
Carfilzomib	for previously treated multiple myeloma in adults	Red	August 2017 MCC
Carnitine	Carnitine deficiency	Red	Subject to NHS England commissioning policies
Carteolol 2% eye drops	Glaucoma	Black	August 2017 MCC
Carvedilol	Prevention of variceal bleeding in patients with portal hypertension and chronic liver disease	Green	August 2016 MCC - In place of propranolol for this condition.
Caspofungin	Antifungal	Red	
Caverject	Erectile dysfunction	Green	Usually second line to PDE type 5 inhibitors
Cefixime	For use in genito-urinary medicine	Red	March 2016 MCC - Confirmation of formulary status
Cerazette	Contraception	Green	
Certolizumab	RA/psoriatic arthritis	Red	As an option for the management of psoriatic arthritis in line with NICE TA 199
Certolizumab pegol	in combination with methotrexate for treating active rheumatoid arthritis in adults	Red	Nov 2016 MCC
Certolizumab pegol	treating active psoriatic arthritis after inadequate response to DMARDs	Red	June 2017 MCC
Cetirizine	Hayfever & allergic rhinitis	Green	Ratified following MCC February 2015. Refer to Vale of York CCG medal rankings for hayfever & allergic rhinitis formulary choices http://www.valeofyorkccg.nhs.uk/rss/index.php?id=medal-ranked-drugs
Cetraben Bath	Bath oil / additives	Black	April 2016 MCC - See Emollient Medal Ranking
Cetuximab	Cancer	Red	
Chlorambucil	Cancer	Red	
Chlordiazepoxide	Alcohol dependence	Green	For Alcohol withdrawal only
Chondroitin sulfate	Osteoarthritis	Black	Not recommended NICE clinical guidance 59 Osteoarthritis
Ciclosporin (oral)	Includes rheumatoid arthritis, psoriasis, atopic dermatitis	Amber - shared care	Shared care for the indications listed in the guideline only
Ciclosporin	Renal/liver transplant	Amber - shared care	
Ciclosporin topical formulations e.g. 0.06% eye drops or 0.2% eye ointment (unlicensed)	Ocular inflammatory disorders when topical steroids are not tolerated or ineffective	Black	Updated CCG position May 2016 MCC

Ciclosporin 1mg/ml eye drops	Treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes. As per NICE TA	Amber - consultant initiation, then for GP prescribing with 6 monthly review by specialist	https://www.nice.org.uk/guidance/ta369
Cidofovir	CMV retinitis	Red	Subject to NHS England commissioning policies
Cilostazol	Intermittant claudication	Black	NICE TA 223 Peripheral arterial disease not recommended
Cinacalcet	Secondary hyperparathyroidism in patients with end-stage renal disease who are not suitable for parathyroidectomy	Amber - shared care	
Cinacalcet	Primary hyperparathyroidism	Amber - shared care	Use is restricted to use in those who decline or are considered unsuitable for surgery.
Ciprofloxacin	Restricted as per North Yorkshire Antimicrobial guidelines.	Green	March 2016 MCC - Confirmation of formulary status
Cisplatin	Cancer	Red	
Cladribine	Multiple sclerosis	Black	Subject to NHS England commissioning policies
Clindamycin 1% Gel	Acne	Black	March 2016 MCC - Topical antibiotic therapy alone not clinically appropriate
Clinitas Gel	Mild dry eye	Green	May 2016 MCC - with preservative Option
Clinitas Multi	Significant dry eye	Green	May 2016 MCC - preservative free option - significant dry eye should never be treated with preserved preps
Clinitas	Significant dry eye	Amber - specialist recommendation	May 2016 MCC - preservative free option - significant dry eye should never be treated with preserved preps
Clobazam	Insomnia	Grey	
Clodronate	Osteolytic lesions, hypercalcaemia and bone	Amber	
Clofarabine	Cancer	Red	
Clomifene	Subfertility	Red	
Clonazepam	Insomnia	Grey	Ratified following MCC February 2015. http://www.valeofyorkccg.nhs.uk/rss/index.php?id=medal-ranked-drugs
Clonazepam	Epilepsy	Black	Formulary review - epilepsy specialists for adult/children services advise this is not used
Clonidine (all strengths)	Hypertension	Red	August 2016 MCC - Confirmation of formulary position
Clonidine 25mcg	Menopausal flushing	Green	August 2016 MCC - Confirmation of formulary position
Clozapine	Schizophrenia	Red	
Coaguchek/ InRatio2 PT/INR anticoagulation INR self-monitoring strips	INR anticoagulation monitoring	Black	The CCG does not commission the prescribing of anticoagulant test strips for home testing. The commissioned service is via York Hospital anticoagulant clinic. Coaguchek appeal rejected. Decision ratified following MCC February 2015.
Co-Beneldopa (benserazide+levodopa)	Parkinsons Disease	Amber - specialist recommendation	June 2017 MCC - Conformation of commissioning position
Co-Careldopa (carbidopa+levodopa)	Parkinsons Disease	Amber - specialist recommendation	June 2017 MCC - Conformation of commissioning position
Co-Careldopa (levodopa+carbidopa) and Entacapone	Parkinsons Disease	Amber - specialist recommendation	June 2017 MCC - Conformation of commissioning position
Co-careldopa (Duodopa) intestinal gel	Parkinsons Disease	Amber - specialist recommendation	NHS England now responsible for the commissioning arrangements for this specialist treatment. Not for GP prescribing.
Co-Cyprindiol (Dianette) tabs	Contraception	Green	
Co-enzyme Q10	Statin induced myopathy	Black	Nutraceuticals, not listed on ACBS list, CCG policy in development
Co-enzyme Q10 (Ubidecarnone)	Other indications e.g. Fredreichs ataxia	Grey	
Colesevalam	Lipid lowering	Grey	
Colesevelam	Pruritus	Black	August 2016 MCC
Colestyramine 4g sachets	licenced indications	Green	
Colestyramine	Cholesterol	Green	August 2016 MCC - Confirmation of formulary status
Colestyramine	Itching and stones	Amber - specialist initiation	August 2016 MCC - Confirmation of formulary status
Colistimethate sodium Dry powder inhaler, 125mg/capsule	Cystic fibrosis	Red	NICE TA 276, treating pseudomonas lung infection in cystic fibrosis. As per NHS England commissioning policies.
Colistimethate sodium for nebulisation (e.g. Colomycin®, Promixin®)	Bronchiectasis	Red	MCC May 2015 - Hospital specialist only until the pathway is formally reviewed at MCC.
Collagenase clostridium histolyticum (CCH)	treating Dupuytren's contracture	Red	August 2017 MCC
Colomycin	Cystic fibrosis	Amber - shared care	As per NHS England policies for CF
COPD drugs for Management in Primary Care (see link to pathway)	COPD	Green	Management of COPD in Primary Care MCC June 2017
Co-proxamol (unlicensed)	Mild-moderate pain	Black	Refer to MHRA advice
Co-trimoxazole	Prophylaxis of infections e.g. pneumocystis carinii	Amber - specialist recommendation	March 2016 MCC - Confirmation of formulary status
Crizotinib	Cancer	Red	
Cyclophosphamide	Rheumatoid arthritis (unlicensed)	Red	
Cyclophosphamide	Cancer	Red	

Cyproterone	All other licensed conditions	Amber - specialist initiation	August 2016 MCC - Confirmation of formulary status
Cyproterone	Prostate cancer	Green	August 2016 MCC - Confirmation of formulary position
Cytarabine	Cancer	Red	
Dabigatran	Stroke prevention in AF, treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism	Green	Refer to York and Scarborough formulary and/or CCG website for guidelines including anticoagulation choices stroke prevention in AF
Daclizumab	an option for treating multiple sclerosis in adults	Red	May 2017 MCC - NHSE commisisoned
Danazol	Endometriosis; Benign fibrocystic breast disease	Amber - specialist recommendation	April 2016 MCC - Confirmation of formulary status
Dapagliflozin	Type 2 diabetes	Green	NICE TA 288. In combination therapy for treating type 2 diabetes. June 2016 MCC - As an option as monotherapy for treating type 2 diabetes as per NICE guidance TA390. Treatment of type 2 diabetes as part of Triple therapy in line with NICE TA 418 - MCC Jan 17
Dapoxetine	Premature ejaculation	Black	CCG policy
Dapsone	Treatment of rare infections	Red	March 2016 MCC - Confirmation of formulary status
Darbepoetin	Anaemia associated with chronic renal failure	Amber - shared care	
Darbepoetin alfa and epoetin alfa, beta, theta and zeta	Anaemia in people with cancer who are receiving chemotherapy	Red	
Darifenacin	Urinary incontinence	Green	second line choice should be based on cost as all options are equally effective
Daunorubicin	Cancer	Red	
Dasatinib	Chronic myeloid leukaemia	Red	
Decitabine	Cancer	Black	NICE TA 270-Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal), refer to NHS England position
Deferasirox	Iron overload	Red	Refer to NHS England
Deferiprone	Iron overload	Red	Refer to hospital trust formulary. NHS England policy under development.
Degarelix injection	advanced hormone-dependent prostate cancer	Amber- specialist initiation	Oct 2016 MCC - In line with NICE TA404
Dehydroepiandrosterone (DHEA)	Low mood or low libido in post-menopausal women	Red	
Delamanid (Delyba®)	Drug resistant tuberculosis	Red	MCC August 2015 - updated NHS England positions. Not for GP prescribing.
Demeclocycline	Infections	Red	March 2016 MCC - Confirmation of formulary status
Demeclocycline	SIADH	Amber- specialist recommendation	March 2016 MCC - Confirmation of formulary status
Denosumab (Prolia®)	Osteoporosis	Amber- shared care	NICE TA 204- Prevention of osteoporotic fractures in post-menopausal women. Also see CCG medal ranking.
Denosumab (Xygeva®)	Prevention bone metastases from solid tumours	Red	NICE TA 265- Bone metastases denosumab – a recommended option instead of a bisphosphonate for preventing skeletal-related events caused by bone metastases from solid tumours. Not recommended for bone metastases from prostate cancer.
Dermamist Spray	Sprays	Green - Third line	Use only when application without touching skin is reqd. April 2106 MCC - See Emollient Medal Ranking
Dermol Cream	Antimicrobial -Use ONLY for short term use for infected skin	Green - Third line	April 2016 MCC - See Emollient Medal Ranking
Dermol Lotion	Bath and Shower with Antimicrobial	Green - First line	April 2016 MCC - See Emollient Medal Ranking
Dermol Wash Emulsion	Bath and Shower with Antimicrobial	Black	April 2016 MCC - See Emollient Medal Ranking
Dermol 200 Shower Emollient	Bath and Shower with Antimicrobial	Black	April 2016 MCC - See Emollient Medal Ranking
Dermol 600 Bath Emollient	Bath and Shower with Antimicrobial	Green - Second line	April 2016 MCC - See Emollient Medal Ranking
Desloratadine (oral antihistamine)	Hayfever & allergic rhinitis	Green	Ratified following MCC Feb 15. Refer to Vale of York CCG medal rankings for hayfever & allergic rhinitis formulary choices http://www.valeofyorkccg.nhs.uk/rss/index.php?id=medal-ranked-drugs
Desmopressin	Diabetes insipidus	Amber- specialist recommendation	April 2016 MCC - Confirmation of formulary status
Desmopressin 25/50 mcg oral lyophilisate (Noqdirna®)	symptomatic treatment of nocturia due to idiopathic nocturnal polyuria	Amber- specialist recommendation	May 2017 MCC
Desunin 20mcg (800iu)	Vitamin D for insufficiency	Green	Feb 16 MCC Second Line Option - See Oral Vit D Medal Ranking
Dexamethasone Intravitreal implant (Ozurdex®)	Retinal vein occlusion, uveitis and diabetic macular oedema	Red	NICE TA 229 Recommended for specified people with macular oedema due to retinal vein occlusion. Uveitis MCC recommendation January 15 to be used by the ophthalmology specialist in accordance with the treatment protocol. MCC August 2015 approved in line with NICE TA 349.
Dexamethasone	for treating non-infectious uveitis	Red	Aug 2017 MCC
Dexamfetamine	ADHD	Amber - shared care	
Diazepam	Insomnia	Grey	Ratified following MCC February 2015. http://www.valeofyorkccg.nhs.uk/rss/index.php?id=medal-ranked-drugs
Diazoxide	chronic intractable hypoglycaemia	Amber- specialist recommendation	April 2016 MCC - Confirmation of formulary status
Diclofenac 0.1% eye drops	Hayfever & allergic rhinitis	Grey	Ratified following MCC February 2015. Refer to Vale of York CCG medal rankings for hayfever & allergic rhinitis formulary choices http://www.valeofyorkccg.nhs.uk/rss/index.php?id=medal-ranked-drugs
Diclofenac 3% gel	Actinic keratosis	Green	But refer to CCG primary care actinic keratosis pathway
Dicycloverine	gastrointestinal spasm	Black	August 2017 MCC
Didanosine	Cancer	Red	
Diloxanide furoate	For the treatment of amebiasis	Red	March 2016 MCC - Confirmation of formulary status
Diltiazem 2% rectal cream	Anal fissures (unlicensed)	Black	May 2017 MCC
Diltiazem 2% rectal ointment	Anal fissures (unlicensed)	Green	After failure of GTN ointment (unlicensed "special") May 2017 MCC

Dimethyl fumarate	moderate to severe plaque psoriasis	Red	MCC October 2017
Disulfiram	Alcohol dependence	Amber - specialist initiation	If prescribed in conjunction with alcohol misuse service. Otherwise it is RED
Docetaxel	Cancer	Red	
Donepezil	Alzheimer's disease	Amber - specialist initiation	Updated position from Leeds & York Mental Health Trust January 2015. For use as per NICE guidance
Dornase alpha	Cystic fibrosis	Amber - shared care	
Dorzolamide eye drops	Glaucoma	Amber - specialist recommendation	Aug 2017 MCC - First line Carbonic anhydrase inhibitor
Dorzolamide PF eye drops	Glaucoma	Amber - specialist recommendation	August 2017 MCC
Dorzolamide + timolol PF eye drops	Glaucoma	Amber - specialist recommendation	August 2017 MCC
Doublebase	Creams/Gels for everyday use, frequent application.	Green - Third line after Epimax	April 2016 MCC - See Emollient Medal Ranking
Doublebase Emollient Bath additive	Bath oil / additives	Black	April 2016 MCC - See Emollient Medal Ranking
Doublebase Emollient Shower Gel	Gel/Washes/Soap substitute	Black	April 2016 MCC - See Emollient Medal Ranking
Doxazosin MR tablets (All brands including Cardura XL®)	Hypertension and benign prostate hyperplasia	Black	January 2015 MCC recommendation
Doxorubicin (Caelyx)	Cancer	Red	
Doxycycline (oral)	Posterior blepharitis	Green	June 2016 MCC - Preferred antibiotic when oral antibiotic treatment required
Dronedarone	Atrial fibrillation	Amber - shared care	Re-classified in light of MHRA warnings
Dulaglutide weekly	Type 2 diabetes	Green	Sept 2016 MCC - Considered locally as first line weekly preparation after exenatide plain in cohort of patients that require daily home visits from a nursing team. Exenatide weekly is an alternative option after this in these cases.
Duodopa® intestinal gel (Levodopa/carbidopa)	Parkinson's Disease	Red	NHS England now responsible for the commissioning arrangements for this specialist treatment
E45 Bath Oil	Bath oil / additives	Black	April 2016 MCC - See Emollient Medal Ranking
E45 lotion	Lotion - NOT routinely recommended locally, as they do not provide enough of a barrier. In select circumstances, these may be useful for application to hairy areas, skin folds, face or scalp.	Green - Third line	April 2016 MCC - See Emollient Medal Ranking
E45 Wash Cream	Gel/Washes/Soap substitute	Black	April 2016 MCC - See Emollient Medal Ranking
Edoxaban 15mg, 30mg & 60mg tablets (Lixiana®)	Stroke prevention and systemic embolism in people with non valvular atrial fibrillation	Green	Approved as an option at Nov 15 MCC to prevent stroke and systemic embolism in people with non-valvular AF who have one or more risk factors
Edoxaban (Lixiana®)	Treatment /prevention of recurrent DVT and PE	Green	Approved following Sept 15 MCC as an option for treating DVT/PE alongside the other commissioned NOAC's and warfarin as per NICE TA 354.
Efalex®(omega fish oils)	Improve eye and brain function	Grey	Not licensed and no recommendation for use by National Advisory Committee on Borderline Substances. Not expected to be routinely commissioned.
Eflornithine 11.5% cream (Vaniqa®)	Facial hirsutism in women	Green	Supported for use in patients where there is an underlying clinical condition identified as the cause of hirsutism. Not commissioned for familial and idiopathic hirsutism.
Eltrombopag	Chronic immune (idiopathic) thrombocytopenic purpura (ITP)	Red	
Elbasvir-grazoprevir	an option for treating genotype 1 or 4 chronic hepatitis C in adults,	Red	Nov 2016 MCC NHSE commissioned
Eluxadoline	irritable bowel syndrome with diarrhoea	Amber - specialist initiation	MCC October 2017
Emedastine eye drops	Hayfever & allergic rhinitis	Grey	Ratified following MCC February 2015. Refer to Vale of York CCG medal rankings for hayfever & allergic rhinitis formulary choices http://www.valeofyorkccg.nhs.uk/rss/index.php?id=medal-ranked-drugs
Emollin Spray	Sprays	Green - Third line	Use only when application without touching skin is reqd. April 2106 MCC - See Emollient Medal Ranking
Empagliflozin	Type 2 diabetes	Green	NICE TA 336 recommends as a treatment option. (MCC April 2015). June 2016 MCC - As an option as monotherapy for treating type 2 diabetes as per NICE guidance TA390
Emulsiderm	Bath and Shower with Antimicrobial	Green - First line	April 2016 MCC - See Emollient Medal Ranking
Emulsifying Ointment	Greasy/ Very Greasy Ointments for very dry skin and/or acute flares.	Green - First line	April 2016 MCC - See Emollient Medal Ranking
Entacapone	Parkinson's Disease	Amber - specialist recommendation	June 2017 MCC - Conformation of commissioning position
Entecavir	Hepatitis B	Amber - shared care	
Enzalutamide	Cancer	Red	
Epiduo topical gel	Mild acne	Green - Second line	June 2016 MCC - 2nd line topical therapy when combination of benzyl peroxide and retinoid is required.
Epimax Cream	Creams/Gels for everyday use, frequent application.	Green - First line	April 2016 MCC - See Emollient Medal Ranking
Epinastine eye drops	Hayfever & allergic rhinitis	Grey	Ratified following MCC February 2015. Refer to Vale of York CCG medal rankings for hayfever & allergic rhinitis formulary choices
Eplerenone	Heart failure following MI	Green	
Epoprostenol	Pulmonary hypertension	Red	NHS England commissioned from specialist centres only
Eribulin	Cancer	Red	Refer to Cancer Drugs Fund. Any prescribing supported by NHS England will be prescribed by the specialist.

Erlotinib	Chronic myeloid leukaemia	Red	
Erythropoetin (Epoetin)	Anaemia associated with chronic renal failure	Amber - shared care	
Escitalopram	Depression	Green	Isomer of citalopram. Citalopram is now off-patent and represents better value for money compared to escitalopram.
Eslicarbazepine	Epilepsy	Black	Formulary review - epilepsy specialists for adult/children services advise this is not used
Esomeprazole	PPI- GI ulcer/NSAID gastric protection	Black	
Estramustine	Cancer	Red	
Etanercept	Licensed indications approved by NICE	Red	Commissioned as per NICE biologics pathway(s). Not for GP prescribing.
Etanercept	plaque psoriasis in children and young people	Red	August 2017 MCC
Etanercept biosimilar – (Benepali®)	In combination with methotrexate, is recommended as option for treating rheumatoid arthritis, and can be used as monotherapy for people who cannot take methotrexate because it is contraindicated or because of intolerance.	Red – Specialist prescribing only	Feb 16 MCC - Approved in line with NICE TA375
Etelcalcetide	Etelcalcetide	Red	July 2017 MCC - NHSE commissioned
Etoposide	Cancer	Red	
Eucerin Intensive cream	Urea containing Preparations	Green - Third line after Flexitol10%Urea Crm	April 2016 MCC - See Emollient Medal Ranking
Everolimus	Cancer	Red	July 2017 MCC - NHSE commissioned
Evolocumab	primary hypercholesterolaemia or mixed dyslipidaemia.	Red	Oct 2016 MCC - In line with NICE TA394 - lipid specialist initiation and prescribing
Evra patch	Contraception	Grey	Expected to be commissioned as an option for patients who are unsuitable for oral contraceptives or LARC
Exemestane	Breast cancer	Amber - specialist initiation	Prescribe generically
Exenatide once weekly	Type 2 diabetes	Green	NICE TA 248. Considered locally after exenatide plain in cohort of patients that require daily home visits from a nursing team.
Exenatide	Type 2 diabetes	Amber -specialist recommendation	Green if undertaken specialist training. Amber for non trained clinicians
Ezetimibe (as per NICE guidance)	Lipid lowering	Green	As per NICE TA 132
Ezetimibe	Treating primary heterozygous-familial and non-familial hypercholesterolaemia	Green	March 2016 MCC - As per NICE TA385
Fampridine	Multiple sclerosis	Black	http://www.england.nhs.uk/wp-content/uploads/2013/04/d04-ps-d.pdf
Febuxostat	chronic gout	Green - Second line after Allopurinol	May 2017 MCC - Use as a second-line treatment in people with chronic symptomatic gout who are intolerant of allopurinol, or for whom allopurinol is contraindicated.
Fentanyl patches	Management of severe chronic pain	Green	Formulary choices are Mezolar, Matrifen and Fencino (note concern over peanut/soya allergy with Fencino). Ratified following MCC February
Ferric maltol	mild to moderate iron deficiency anaemia (Hb >9.5g/dL) in patients with inflammatory bowel disease (IBD).	Amber -specialist recommendation	Sept 2017 MCC
Fesoterodine	Urinary incontinence	Black	Fesoterodine is a pro-drug of tolterodine.
Fexofenadine (oral antihistamine)	Hayfever & allergic rhinitis	Green	Ratified following MCC February 2015. Refer to Vale of York CCG medal rankings for hayfever & allergic rhinitis formulary choices http://www.valeofyorkccg.nhs.uk/rss/index.php?id=medal-ranked-drugs
Fidaxomicin	<i>Clostridium difficile</i> infection	Amber -specialist recommendation	March 2017 MCC Change from Red to Amber - Cons Microbiologist recommendation only
Fifty : 50 Ointment	Greasy/ Very Greasy Ointments for very dry skin and/or acute flares.	Green - Third line after Emuls Oint	April 2016 MCC - See Emollient Medal Ranking
Filgrastim	Recombinant human granulocyte-colony stimulating factor (G-CSF) - neutropenia	Red	
Finacea	Acne	Black	March 2016 MCC - Not clinically appropriate for acne treatment
Finacea	Rosacea	Green	
Fingolimod	Multiple sclerosis	Red	
Flavoxate	Urinary incontinence	Black	Not routinely commissioned, as per NICE guidance (CG40)
Flexitol 10% urea cream	Urea containing Preparations	Green - First line	April 2016 MCC - See Emollient Medal Ranking
Flexitol Heal Balm	Urea containing Preparations	Green - Third line after Flexitol10%Urea Crm	April 2016 MCC - See Emollient Medal Ranking
Fludarabine	Cancer	Red	
Flunitrazepam	Insomnia	Grey	Ratified following MCC February 2015. http://www.valeofyorkccg.nhs.uk/rss/index.php?id=medal-ranked-drugs
Fluocinolone acetonide intravitreal implant	Diabetic macular oedema	Black	NICE TA 271- not recommended
Flutamide	Anti-androgens	Amber - shared care	
5-Fluorouracil 5% cream	Actinic keratosis	Green	1st line choice in CCG actinic keratosis primary care pathway
Fluorouracil 0.5% and salicylic acid (Actikerall®)	Actinic keratosis	Green	Treatment options in CCG actinic keratosis primary care treatment pathway (currently 2nd most cost effective option)
Flupentixol decanoate depot (Depixol®)	Schizophrenia/psychosis	Amber - specialist initiation	May 2017 MCC
Fluphenazine decanoate depot	Schizophrenia/psychosis	Amber - specialist initiation	May 2017 MCC

Fluticasone/ salmeterol 125/25 MDI and 250/25 MDI (Sirdupla)	Asthma	Green	MCC August 2015 - Offers better value compared with Seretide Evohaler
Fluticasone furoate/vilanterol (Relvar Ellipta)	Asthma	Black	Safety concerns have been raised and need to be addressed.
Fluticasone furoate nasal spray	Hayfever & allergic rhinitis	Green	Ratified following MCC February 2015. Refer to Vale of York CCG medal rankings for hayfever & allergic rhinitis formulary choices http://www.valeofyorkccg.nhs.uk/rss/index.php?id=medal-ranked-drugs
Fluticasone dipropionate 50 microgram nasal spray	Hayfever & allergic rhinitis	Green	Ratified following MCC Feb 15. Refer to Vale of York CCG medal rankings for hayfever & allergic rhinitis formulary choices http://www.valeofyorkccg.nhs.uk/rss/index.php?id=medal-ranked-drugs
Fluticasone propionate/azelastine (Dymista)	Allergic rhinitis	Black	(Appeal MCC January 2015) Prescribing a low cost antihistamine and steroid nasal spray as single items represents better overall value to the NHS. Refer to medal ranking for CCG product choices http://www.valeofyorkccg.nhs.uk/rss/index.php?id=medal-ranked-drugs
Flutter device	Oscillating positive pressure device to improve/ease airway clearance	Amber - specialist initiation	Replacement devices may be provided within primary care
Fosavance® (alendronate/vitamin D combination)	All conditions	Black	May 2017 MCC
Fosfomycin	In adults for urinary tract infections resistant to standard agents (unlicensed)	Amber - consultant microbiologist recommendation	June 2015 MCC - licensed product approved for use (in place of unlicensed product)
Fultium-D3 500 mcg (20000iu) caps	Vitamin D for deficiency	Green	Feb 16 MCC Second Line Option - See Oral Vit D Medal Ranking
Fultium-D3 20mcg (800iu) caps	Vitamin D for insufficiency	Green	Feb 16 MCC Try to avoid Use 3rd line if needed - See Oral Vit D Medal Ranking
Fultium-D3 2740iu/ml (67iu/drop)	Vitamin D for replete	Green	Feb 16 MCC Second Line Option - See Oral Vit D Medal Ranking
Fulvestrant	Breast cancer	Black	NICE TA 239. Breast cancer (metastatic). Not recommended post-menopause in oestrogen dependent metastatic disease, or if disease returned/worsened after anti-oestrogens. MCC August 2015 - Not supported on grounds of clinical and cost effectiveness on the proposed 4th line use (after tamoxifen, anastrozole / letrozole and exemestane.)
Fumaderm (fumaric acid esters)	Psoriasis (unlicensed)	Red	Position confirmed at Sept 15 MCC - for plaque psoriasis unresponsive to conventional therapy (topical agents, phototherapy) or where contraindicated.
Galantamine	Alzheimers disease	Amber - specialist initiation	Updated position from Leeds & York Mental Health Trust January 2015. For use as per NICE guidance
Gamolenic acid	All indications	Black	
Ganciclovir	Maintenance of Cytomegalovirus (CMV) retinitis in AIDS patients. CMV disease in immunocompromised & AIDS patients. Use in Liver Transplant patients.	Red	As per NHS England
Gedarel	Contraception	Green	May 2016 MCC
Gemcitabine	Cancer	Red	
Gentamicin for nebulisation	Bronchiectasis	Red	MCC May 2015 - Hospital specialist only until the pathway is formally reviewed at MCC.
Glatiramer acetate	Multiple sclerosis	Red	
GLP-1 agonists (exanetide, liraglutide)	Type 2 diabetes	Green	As per NICE
Glucodrate	management of high output stoma/short bowel syndrome	Amber - specialist initiation	Sept 2017 MCC
GlucoRx® blood glucose monitoring device	Diabetes mellitus	Green	MCC August 2015 - The CCG blood glucose monitoring device of choice for type 2 diabetes.
Glucosamine (all products)	Osteoarthritis	Black	Not recommended for use NICE CG59 Osteoarthritis
Gluten free products	Autism	Black	No recommendation for use by National Advisory Committee on Borderline Substances
Golimumab injection	Licensed indications approved by NICE	Red	Not for GP prescribing.
Goserelin	Prostate cancer, endometriosis, breast cancer	Amber - specialist recommendation	
Granisetron patch	Prevention of nausea and vomiting associated with moderately or highly emetogenic chemotherapy	Grey	Requests to use subject to formal application to Medicines Commissioning Committee for any indication
Granisetron (subcut)	second line to SC ondansetron for use in palliative care when use of a syringe driver is not suitable	Green	Sept 2017 MCC
Grazax (Grass pollen extract)	Grass pollen induced rhinitis	Black	Economic analysis not sufficiently robust (SMC)
Growth Hormone	Growth hormone deficiency	Amber - shared care	
Guaifenesin	Fibromyalgia (unlicensed)	Grey	
Guanfacine	Treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 6 to 17.	Red	Oct 2016 MCC - 3rd line after dexamphetamine / lisdexamfetamine and atomoxetine has been tried.
Haloperidol decanoate depot	Schizophrenia/psychosis	Amber - specialist initiation	May 2017 MCC
Hepatitis B vaccine	Occupational Health	Black	Vaccine cost should be charged to the patients employee
Hepatitis B vaccine	Travel	Black	Should be prescribed on a private basis - National policy

HIV anti-virals	HIV	Red	Commissioned by NHS England, not for GP prescribing. Includes updated NHS E decisions (Elvitegravir/cobicistat/tenofovir) following MCC August 2015.
Holoclax	limbal stem cell deficiency after eye burns	Red	Sept 2017 MCC
Humulin R U500 Insulin	Diabetes mellitus	Red	*Updated to allow some patients who have failed to tolerate the newer alternative (insulin degludec) to move back to U500. Decision ratified following MCC February 2015.
Humalog 200 unit Kwipen	Diabetes mellitus requiring insulin	Green	Approved Nov 15 MCC Where a rapid acting insulin analogue is indicated. Refer to NICE.
Hydrocortisone modified release tablet (Plenadrin)	Addisons Disease	Black	Robust clinical and cost evidence fails to demonstrate clear advantages over standard hydrocortisone.
Hydrocortisone rectal	Ulcerative colitis and other rectal / GI conditions	Amber - specialist recommendation	April 2016 MCC - Confirmation of formulary status
Hydrocortisone	Adrenal insufficiency	Green	April 2016 MCC - Confirmation of formulary status
Hyaluronic acid (and derivatives) - Synvisc®	Osteoarthritis of the knee	Black	Not routinely commissioned, as per NICE guidance (CG059)
Hydromol cream	Creams/Gels for everyday use, frequent application.	Black	April 2016 MCC - See Emollient Medal Ranking
Hydromol Bath and Shower Emollient	Bath oil / additives	Green - second line	April 2016 MCC - See Emollient Medal Ranking
Hydromol Ointment	Greasy/ Very Greasy Ointments for very dry skin and/or acute flares.	Green - Third line after Emuls Oint	April 2016 MCC - See Emollient Medal Ranking
Hydroxycarbamide	Myeloproliferative disease, psoriasis	Amber - shared care	
Hydroxychloroquine	Rheumatoid arthritis	Amber - shared care	
Hylo Forte	Significant dry eye	Amber - specialist recommendation	May 2016 MCC - preservative free option - significant dry eye should never be treated with preserved preps
Ibandronic acid 150mg tablets	Osteoporosis	Green	See medal ranking for CCG choices http://www.valeofyorkccg.nhs.uk/rss/data/uploads/prescribing/medal-ranked-drugs/medal-ranking-oral-bisphosphonates-voyccg-march-2015.pdf
Ibandronate (oral)	improving breast cancer survival	Amber - specialist initiation	July 2017 MCC
Ibandronic acid injection (Bonviva®)	Osteoporosis	Red	See medal ranking for CCG choices http://www.valeofyorkccg.nhs.uk/rss/data/uploads/prescribing/medal-ranked-drugs/medal-ranking-oral-bisphosphonates-voyccg-march-2015.pdf
ICaps	Antioxidants for ocular health	Black	
Icatabant	Hereditary angiooedema	Red	Commissioning position as per NHS England policy
Idarubicin	Cancer	Red	
Idoxuridine in Dimethyl Sulfoxide (Herpid)	Cancer	Black	DLCV
Ikervis	Severe blepharitis / dry eye / keratitis	Amber - specialist initiation	May 2016 MCC
Iloprost	Pulmonary hypertension	Red	
Ilube	Filamentary keratitis	Amber - specialist recommendation	May 2016 MCC
Imatinib	Chronic myeloid leukaemia	Red	Also refer to Cancer Drugs Fund.
Imiglucerase	Gauchers disease	Red	Subject to NHS England commissioning policies
Imiquimod	Actinic keratosis and Basal cell carcinoma	Amber - specialist recommendation	August 2016 MCC - Confirmation of formulary position
Imiquimod	Genital warts	Red	August 2016 MCC - Confirmation of formulary position
Immunglobulins	Various indications	Red	Commissioning position as per NHS England policy applying DH National Immunoglobulin stratification
Inegy (simvastatin + ezetimibe)	Lipid lowering	Black	
Infliximab infusion	Licensed indications approved by NICE	Red	Biosimilar (Remsima) approved as per application June 2015. Not for GP prescribing.
Ingenol mebutate gel (Picato®)	Actinic keratosis	Green	Treatment option in CCG actinic keratosis primary care treatment pathway. Restricted as less cost effective than topical fluorouracil.
Insuject™ non needle device	Non needle insulin delivery device	Black	Evidence indicates associated with pain/bruising. Local diabetes specialist opinion does not support their use.
insulin aspart (Fiasp®)	Diabetes mellitus in adults	Black	May 2017 MCC
Insulin aspart (Novarapid®) PumpCart cartridges 1.6mL	Diabetes mellitus in adults	Amber - specialist initiation	March 2015 MCC
Insulin degludec 100 units/mL / liraglutide 3.6 mg/mL (Xultophy®)	Adults with type 2 diabetes	Black	November 2015 MCC. Other than offering a single injection, additional clinical benefits had not been demonstrated.
Insulin degludec (Tresiba)	Diabetes mellitus in adults	Amber - specialist initiation	Position updated following Sept 15 MCC - Toujeo is the 1st choice high strength insulin. Insulin degludec is an option after Toujeo for use in patients for whom insulin U500 would otherwise be prescribed and for patients with significant nocturnal hypoglycaemia. Toujeo® is the 1st choice high strength insulin. Insulin degludec would be an option after Toujeo®.
Toujeo® 300 units/ml (insulin glargine) pre-filled pen *HIGH STRENGTH INSULIN*	Diabetes mellitus	Green	Approved following Sept 15 MCC for patients on insulin glargine (Lantus®) who require: • High dose (60+ units) per dose • Large volume of insulin + local site reactions • Twice daily insulin NOTE: Toujeo 300mg/mL is not bioequivalent to insulin glargine 100mg/mL.
Insulin U500 - Humulin R	Severe insulin resistance	Black	Replaced by insulin degludec
Interferons1,2,3, α - and β -	All licensed indications	Red	
Intrathecal drug delivery	Chronic non cancer pain	Black	
Intrathecal drug therapy	Cancer pain	Red	Subject to NHS England commissioning policies, not for GP prescribing. Updated following MCC August 2015

Invicorp®	Erectile dysfunction	Grey	
Invita-D3 625 micrograms (25 000ui)/mL	Vitamin D for deficiency & insufficiency	Green	Feb 16 MCC Try to avoid Use 3rd line if needed - See Oral Vit D Medal Ranking
Ipilimumab	Cancer	Red	NICE TA 268-Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Irinotecan	Cancer	Red	
Irinotecan (Pegylated liposomal)	Cancer	Black	May 2016 MCC
Isocarboxazid	Cancer	Black	DLCV
Isopto plain drops	Mild dry eye	Green	May 2016 MCC - with preservative Option
Isotretinoin tablets	Severe acne	Red	As per MHRA advice
Itraconazole	For use as per North Yorkshire Antimicrobial guidelines.	Green	March 2016 MCC - Confirmation of formulary status
Ivabradine	Angina/heart failure	Amber - specialist initiation	(NICE TAG 267)It should be initiated by a heart failure specialist and dose titrated to the maximum tolerated dose
Ivacaftor	Cystic fibrosis	Red	As per NHS England commissioning policy for cystic fibrosis. Not for GP prescribing.
Ivermectin (Soolantra®) cream	topical treatment of inflammatory lesions of rosacea (papulopustular) in adult patients.	Green. 3rd option after failure of metronidazole gel and azaleic acid gel.	Feb 16 MCC - 3rd line option after failure of metronidazole gel and azaleic acid gel. GP to be sure of the diagnosis and must get confirmation if not e.g. by photograph to dermatologist or by OP referral. GP to only prescribe one tube and for patient to be reviewed at eight weeks. Maximum of four months treatment (two tubes) allowed. No evidence of benefit if re-used so do not give further courses.
Ivermectin oral	All conditions	Red	May 2017 MCC - specialist dermatologist use only
IVF drugs	Sub-fertility	Red	
Japanese B encephalitis vaccine	Travel	Black	
Jext (adrenaline pen)	Anaphylaxis	Green	
Kalcipos D® chew tabs & regular tabs Kalcipos D® chew tabs & regular tabs	Calcium & vitamin D supplementation	Grey	See medal ranking guidance for CCG choices.
Ketamine oral liquid (unlicensed)	Chronic pain	Red	Hospital specialist prescribing only for patients who have exhausted other options. (MCC May 2015)
Ketotifen 250 micrograms/mL eye drops	Hayfever & allergic rhinitis	Grey	Ratified following MCC February 2015. Refer to Vale of York CCG medal rankings for hayfever & allergic rhinitis formulary choices http://www.valeofyorkccg.nhs.uk/rss/index.php?id=medal-ranked-drugs
Knox Formula mouthwash	Oral lichen planus (unlicensed)	Red	
Lacosamide	Epilepsy	Amber - specialist initiation	Specialist initiation and supply as per the treatment care plan
Lacri-lube	Dry eye	Green	May 2016 MCC - Preservative-free Option. Ointments usually for night time use
Lactose free infant formulae	Lactose intolerance	Black	July 2017 MCC
Lanreotide	Acromegaly	Amber - shared care	Indications only shared care when agreed in formal shared care guidelines. Indications not included, prescribing should be RED, hospital only
Lanreotide	Complications following pancreatic surgery (unlicensed)	Red	
Lanthanum	phosphate binding	Red	Sept 2017 MCC
Lapatinib	Cancer	Red	Refer to Cancer Drugs Fund. Any prescribing supported by NHS England will be prescribed by the specialist.
Laquinimod	Multiple sclerosis	Black	As per NHS England commissioning policies
Laronidase	Mucopolysaccharidosis I	Red	As per NHS England commissioning policies
Laxido® Paediatric sachets (macrogol 3350)	Chronic constipation/faecal impaction in children as per license	Green	MCC August 2015 the CCG preferred choice when a macrogol is indicated.
Leflunomide	Includes RA	Amber - shared care	Shared care for the indications listed in the guideline only
Lenalidomide	Multiple myeloma	Red	
Lepicol (food supplement)	Maintaining a healthy, regular bowel and irritable bowel	Black	Policy for non medicines (e.g.food supplements) where outwith ACBS criteria currently underway
Lercanidipine tablets	Hypertension	Green	June MCC approved 2nd line after amlodipine.
Letrozole	Breast cancer	Amber - specialist recommendation	Prescribe generically
Leuprorelin	Prostate cancer	Amber - specialist recommendation	Updated CCG position September 2014
Levobunolol PF eye drops	Glaucoma	Black	August 2017 MCC
Levocetirizine (oral antihistamine)	Hayfever & allergic rhinitis	Grey	Ratified following MCC Feb 15. Refer to Vale of York CCG medal rankings for hayfever & allergic rhinitis formulary choices http://www.valeofyorkccg.nhs.uk/rss/index.php?id=medal-ranked-drugs
Levofloxacin	For restricted use	Amber - specialist recommendation	March 2016 MCC - Confirmation of formulary status. For occasional use where penicillin allergy exists
Jaydess 13.5mg interuterine device (levonorgestrel)	Long acting intrauterine contraception	Green	MCC August 2015 - Approved for use by GP practices commissioned to provide contraception services by North Yorkshire County Council.
Lexkizumab	moderate to severe plaque psoriasis	Red	June 2017 MCC
Lid-Care®	Blepharitis (unlicensed)	Grey	
Lidocaine 5% plaster (Versatis®)	Neuropathic pain	Amber - specialist initiation	Feb 2017 MCC - In accordance with updated neuropathic pain flowchart
Linaclotide	IBS with constipation	Green	Restricted to use after antispasmodics, laxatives and antidepressants have failed or due to inadequate response
Linezolid	Antimicrobial	Red	
Liothyronine	Hypothyroidism	Amber -specialist recommendation	April 2016 MCC - Confirmation of formulary status
Liothyronine injection	hypothyroid crisis	Red	July 2017 MCC

Liraglutide 3mg (Saxenda®)	Weight management	Black	November 2015 MCC - Not commissioned, Saxenda® is a new product containing liraglutide licensed for weight management. This product should not be confused with liraglutide 6 mg/mL solution for injection in pre-filled pen (Victoza®) which is only licensed for treatment of type 2 diabetes.
Lisdexamfetamine (Elvanse)	Attention deficit hyperactivity disorder children & adults	Amber - shared care	Jan 2017 MCC - adoption of existing TEWV shared care document
Lithium	Treatment of mania	Amber - shared care	
Lithium	ADHD	Amber - shared care	August 2017 MCC
Lixisenatide (Lyxumia)	Type 2 diabetes	Green	Approved as first line agent within this class of drugs when indicated as per NICE
LMWH (e.g. daltaparin, enoxaparin)	Post surgical prophylaxis of DVT	Red	For use as per NICE guidance (CG046). 4 week course to be prescribed by secondary care.
	VTE prophylaxis following lower limb casting	Red	For use as per NICE guidance (CG092). Course to be prescribed by secondary care.
	Thrombo-prophylaxis in adult out-patients (>16yrs) with non-surgical lower limb immobilisation	Amber - specialist initiation	Joint communication between secondary/primary care agreed MCC January 2015 2 week course to be prescribed by secondary care
Lodoxamide eye drops	Hayfever & allergic rhinitis	Grey	Ratified following MCC February 2015. Refer to Vale of York CCG medal rankings for hayfever & allergic rhinitis formulary choices http://www.valeofyorkccg.nhs.uk/rss/index.php?id=medal-ranked-drugs
Lomustine	Cancer	Red	
Loperamide	Acute diarrhoea	Green	Routinely use the product with lowest acquisition cost (tablets or capsules). Follow specific guidance for high output stoma (see loperamide tablets below)
Loperamide TABLETS	High volume output from stoma	Green	Patients with a stoma should be given the tablet formulation rather than capsules when indicated to reduce stoma output
Loratadine (oral antihistamine)	Hayfever & allergic rhinitis	Green	Refer to Vale of York CCG medal rankings for hayfever & allergic rhinitis formulary choices http://www.valeofyorkccg.nhs.uk/rss/index.php?id=medal-ranked-drugs
Lormetazepam	Insomnia	Grey	Ratified following MCC February 2015. http://www.valeofyorkccg.nhs.uk/rss/index.php?id=medal-ranked-drugs
Lorprazolam	Insomnia	Grey	Ratified following MCC February 2015. http://www.valeofyorkccg.nhs.uk/rss/index.php?id=medal-ranked-drugs
Loxapine inhalation	Mucopolysaccharidosis	Black	NICE TA 286- Terminated appraisal for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder
LPL 63.4%	Bath oil / additives	Green - First line	April 2016 MCC - See Emollient Medal Ranking
Lubiprostone (Amitiza®)	Chronic idiopathic constipation	Amber - specialist initiation	Gastroenterology consultant initiation in line with NICE TA 318. GPs may continue the prescribing when a review after 2 weeks therapy demonstrates benefit.
Lurasidone (Latuda®)	Schizophrenia in adults	Black	Leeds and York Partnership Mental Health NHS Trust have not approved this treatment
MacULEH light (and similar oral eye vitamin preparations)	Age-related macular degeneration (AMD)	Black	August 2016 MCC - Confirmation of formulary position
Macitentan	Pulmonary hypertension	Red	Commissioned by NHS England from specialist centres only
Mannitol dry powder inhaler	Cystic fibrosis	Red	Dry powder for cystic fibrosis (NICE TA 266)
Melatonin	Primary insomnia	Black	Ratified following February 15 MCC
Melatonin	Sleep disorders in adults.	Black	August 2016 MCC - Confirmation of formulary position
Melatonin	Sleep disorders sleep disorders in children with visual problems and learning difficulties, cerebral palsy and autistic spectrum disorders as listed in the guidance	Amber - shared care	Shared care for the indications listed in the guideline only. Shared care lists preferred products or seek advice from MMT. Ratified following February 2015 MCC
Melatonin	Adults with ADHD	Black	Ratified following February 15 MCC
Melatonin	Delayed phase sleep syndrome and parasomnia's	Black	NEW Ratified following February 15 MCC
Melphalan	Chemotherapy	Red	
Memantine	Dementia	Amber - specialist initiation	Updated position from Leeds & York Mental Health Trust January 2015. For use as per NICE guidance
Mepacrine (unlicensed)	Dermatological conditions (DLE, SCLE)	Red	For patients who fail to respond to topical treatments or for whom topical therapy is not appropriate. If an antimalarial is indicated, then mepacrine is used where patients cannot take hydroxychloroquine. Decision ratified following MCC February 2015.
Mepolizumab	All conditions	Red	May 2017 MCC - NHSE commissioned
Mercaptamine	Nephropathic cystinosis	Red	Refer to trust formulary for further comments
Mercaptopurine	Crohns/ulcerative colitis	Amber - shared care	2nd line where azathioprine CI or not tolerated and where indicated as per SC. If indicated for cancer this drug is RED
Mesalazine (Salofalk® MR) granules	Ulcerative colitis	Green	Approved June 2015 Salofalk is a 1st line option alongside Pentasa® and Octasa®.
Metformin SR (2nd line use only)	Diabetes mellitus	Green	
Methadone	Pain	Red	April 2016 MCC - Confirmation of formulary status
Methadone liquid 1mg/1ml s/f, 1mg/1ml, 1mg/ml c/f	Opioid dependence	Green	May 2017 MCC Must be prescribed in conjunction with substance misuse service recovery co-ordinator
Methotrexate (oral) 2.5mg	NON CANCER INDICATIONS includes rheumatology, gastroenterology and dermatology indications as listed in the SCG	Amber -shared care	Indications only shared care when agreed in formal shared care guidelines. Cancer or where no formal shared care - prescribing should be RED, hospital only
Methotrexate (oral) 10mg	All indications for oral treatment in primary care	Black	Recommended that only methotrexate 2.5mg tablets remain formulary choice on patient safety grounds

Methotrexate (subcutaneous)	NON CANCER INDICATIONS includes rheumatology, gastroenterology and dermatology indications as listed in the SCG	Amber - shared care	Indications only shared care when agreed in formal shared care guidelines. Cancer or where no formal shared care - prescribing should be RED, hospital only
Methylodopa	Hypertension	Amber - specialist recommendation	April 2016 MCC - Confirmation of formulary status
Methylnaltrexone	Opioid induced constipation	Amber - specialist recommendation	Restricted to palliative care - An option for patients who have had an inadequate response to standard oral/rectal laxatives
Methylphenidate	ADHD	Amber - shared care	Refer to NICE guidance
Midazolam buccal	Epilepsy	Amber - specialist recommendation	Refer to formulary
Midodrine (Bramox®) tablets	Orthostatic hypotension	Amber - specialist recommendation	Restricted use after failure of standard non pharmacological measures and fludrocortisone. Treatment to be initiated by the specialist to evaluate effectiveness as outlined in policy. August 2015 MCC - formulary position unchanged , new licensed formulation available.
Miglustat	Mild to moderate type 1 Gaucher disease	Red	Refer to hospital trust formulary.
Mifamurtide	Osteosarcoma	Red	NICE TA 235. Recommended as a treatment for specified children, adolescents and young adults - subject to NHS England policy, refer to hospital trust formulary.
Minocycline	Acne	Black	March 2016 MCC - Confirmation of formulary status
Mirabegron tablets 25mg, 50mg	Urinary incontinence	Green	After failure of at least 3 antimuscarinic drugs - refer to treatment pathway
Mirena® intrauterine delivery system	Licensed indications	Green	MCC May 2015
Mitomycin	Cancer	Red	
Mitoxantrone	Cancer	Red	
Modafinil	Narcolepsy in adults	Amber - specialist initiation	MCC March 2016
Modafinil (Provigil®)	Fatigue associated with MS (unlicensed)	Black	MCC May 2015 -Updated following NICE clinical guideline (CG186) for MS.
MolluDab® (contains 5% potassium hydroxide)	Molluscum contagiosum	Black	Ratified following November 2014 MCC
Mometasone furoate nasal spray	Hayfever & allergic rhinitis	Green	Ratified following MCC Feb 15. Refer to Vale of York CCG medal rankings for hayfever & allergic rhinitis formulary choices http://www.valeofyorkccg.nhs.uk/rss/index.php?id=medal-ranked-drugs
Mycophenolate	Immunosuppressant - organ transplantation	Amber - shared care	
Mycophenolate	All Non-transplant indications	Amber - shared care	MCC October 2017
Naftidrofuryl oxalate	Intermittent claudication in peripheral arterial disease	Green	NICE TA 223
Nalmefene (Selincro®)	Reduction of alcohol consumption in adult patients	Prescribing by alcohol specialist service only.	ucral
Naloxegol (Moventig®)	Opioid induced constipation	Green	Approved following Sept 15 MCC for those who have not responded to at least 2 full dose laxatives and dietary advice. NICE TA 345
Naltrexone/bupropion (8mg/90mg) tablets (Mysimba®)	Weight management	Black	November 2015 MCC - Further longer term safety and efficacy data is required before Mysimba® can be recommended for use.
Naltrexone	Alcohol dependence	Red	MCC Jan 17
Naltrexone (low dose)	Multiple sclerosis	Grey	MS Society highlights unknown risks and unproven benefits. Not expected to be routinely commissioned.
Natalizumab	Multiple sclerosis	Red	As per NHS England commissioning recommendations
Natecal D3	Calcium & vitamin D supplementation	Green	See medal ranking guidance for CCG choices.
Nebivolol	Hypertension	Black	January 15 MCC review, current position recommended.
Nedocromil 2% eye drops	Hayfever & allergic rhinitis	Green	Ratified following MCC February 2015. Refer to Vale of York CCG medal rankings for hayfever & allergic rhinitis formulary choices http://www.valeofyorkccg.nhs.uk/rss/index.php?id=medal-ranked-drugs
Nefopam	Pain	Black	April 17 MCC - 6x more expensive than the previous brand (which has been discontinued). There is very little to justify the use of nefopam over other more commonly used non-opioid analgesics.
Nelarabine	Cancer - haematology	Red	
Nicobloc	Part of a smoking cessation programme	Grey	Not expected to be routinely commissioned. No evidence of clinical effectiveness.
Nilotinib	Chronic myeloid leukaemia	Red	Specialist haematology only
Nitrazepam	Insomnia	Grey	Ratified following MCC February 2015. http://www.valeofyorkccg.nhs.uk/rss/index.php?id=medal-ranked-drugs
Nivolumab	an option for previously treated advanced renal cell carcinoma in adults	Red	Jan 17 MCC - In line with NICE TA 417
Non needle insulin devices (Insuject™ & Injex™)	Medical devices to deliver insulin	Black	Evidence indicates the devices being associated with pain and bruising. Local diabetes specialist opinion does not support their use
Nortriptyline	Licensed indications e.g. nocturnal enuresis and off label indications e.g. neuropathic pain, IBS	Green	(MCC recommendation December 2014) Amitriptyline is the preferred agent where either amitriptyline or nortriptyline is recommended as an option. Nortriptyline is expensive and is restricted for use in those with underlying cardiac conditions or where the sedative properties of amitriptyline are not desired or are problematic.

Nuvaring	Contraception	Amber - specialist initiation where on the formulary.	For use where contraceptive pills or patches are not tolerated or not acceptable to the patient. Decision ratified following MCC February 2015
Obeticholic acid	an option for treating primary biliary cholangitis	Red	May 2017 MCC - NHSE commissioned
Obinutuzumab	with bendamustine for treating follicular lymphoma refractory to rituximab	Red	Sept 2017 MCC
Octreotide LA	Acromegaly	Amber - shared care	
Ocuvite preparations	Antioxidants for ocular health	Black	
ODM5	Corneal oedema / Fuchs endothelial dystrophy	Amber - specialist recommendation	May 2016 MCC
Ofatumumab	Cancer - haematology	Red	
Oilatum cream (& junior)	Creams/Gels for everyday use, frequent application.	Green - Second line after Epimax	April 2016 MCC - See Emollient Medal Ranking
Oilatum Gel	Gel/Washes/Soap substitute	Black	April 2016 MCC - See Emollient Medal Ranking
Oilatum Junior Bath	Bath oil / additives	Black	April 2016 MCC - See Emollient Medal Ranking
Oilatum Plus	Bath and Shower with Antimicrobial	Green - Third line	April 2016 MCC - See Emollient Medal Ranking
Oilatum Shower Gel	Gel/Washes/Soap substitute	Black	April 2016 MCC - See Emollient Medal Ranking
Olanzapine oral	Schizophrenia	Amber - shared care	http://www.lhp.leedsth.nhs.uk/common/guidelines/detail.aspx?id=614
Olanzapine embonate (ZypAdhera®)	All indications	Black	May 2017 MCC
Olaratumab	advanced soft tissue sarcoma	Red	Sept 2017 MCC
Olodaterol 2.5mcg inhaler (Striverdi Respimat®)	COPD	Amber - specialist initiation	Feb 2017 MCC. Change of formulary position. Refer to updated COPD pathway.
Olopatidine eye drops	Hayfever & allergic rhinitis	Green	Ratified following MCC Feb 15. Refer to Vale of York CCG medal rankings for hayfever & allergic rhinitis formulary choices http://www.valeofyorkccg.nhs.uk/rss/index.php?id=medal-ranked-drugs
Omalizumab	Allergy medicated asthma	Red	Subject to NICE/NHS England commissioning policies
Omalizumab	Chronic urticaria	Red	This drug was NHSE commissioned but NHSE recently announced that it is now CCG commissioned. January 2016 MCC
Omega 3 (including Omacor)	Secondary prevention of MI	Black	
Omega 3 (including Omacor)	Schizophrenia	Black - feedback from Leeds	
Ondansetron (oral)	chronic nausea and vomiting when other antiemetics are contraindicated or unsuitable.	Green	Sept 2017 MCC
Ondansetron (subcut)	short term use in palliative care when other antiemetics are contraindicated or unsuitable.	Green	Sept 2017 MCC
Ondansetron 4mg tablets (only tablets approved, not lqd or inj)	Diarrhoea +/- nausea associated with irritable bowel disease (unlicensed)	Amber - specialist initiation	Patients would have been seen in primary care and worked through NICE guidance on IBS. If patients had not been offered a tricyclic antidepressant this may be tried first, but not always as depends upon predominant symptoms and would be discontinued if no response.
Opicapone	as adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.	Black	June 2017 MCC
Optivite Plus	Evaporative dry eye	Amber - specialist recommendation	May 2016 MCC
Oral Nutritional Supplements (ONS)	Oral Nutrition	As per guidance (see link)	July 2017 MCC - ONS Guidance update
Oral impact	Dietary supplementation pre-operatively	Red	York Drug & Therapeutics Committee December 2014
Orlistat	Obesity	Green	July 2016 MCC - Confirmation of formulary position - In line with NICE guidance
Orphenadrine Hydrochloride	Parkinsons Disease	Amber - specialist recommendation	June 2017 MCC - Confirmation of commissioning position
Oseltamivir (Tamiflu)	For use when influenza virus circulating - As per NICE guidance	Green	March 2016 MCC - Confirmation of formulary status
Osimertinib	non-small-cell lung cancer	Red	Nov 2016 MCC - NHSE CDF commissioned
Oxcarbazepine	Epilepsy	Amber	
Oxerutins	Oedema associated with chronic venous insufficiency	Grey	Adults specialist recommendation, children specialist initiation
Oxycodone/naloxone - Targinact	Severe pain	Green	(Ratified from December MMC) Individuals who have tried at least 2 other opioids and have intractable opioid induced constipation that has not responded to two full dose laxatives.
Paclitaxel	Cancer	Red	
Paclitaxel as albumin-bound nanoparticles with gemcitabine	untreated metastatic pancreatic cancer	Red	MCC October 2017
Paliperidone long acting injection (LAI)	Schizophrenia	Amber - shared care	May 2017 MCC
Paliperidone oral preps	All conditions	Black	May 2017 MCC
Palivizumab	Respiratory syncytial virus	Red	As per NHS England commissioning recommendations
Palliative Care treatments	see list of drugs in separate document	See List	March 2016 MCC - Confirmation of formulary status in line with newly approved guideline
Panitumumab	Cancer	Red	NHSE Commissioned Apr 2017 MCC

Paraldehyde 50% in olive oil enema 30m	For treatment of epilepsy As per Sheffield treatment guideline	Red	April 2016 MCC - Confirmation of formulary status
Paroxetine	Depression - "continuation only"	Green	May 2017 MCC
Pazoponib	Cancer	Red	
Pegaptinib	Age related macular degeneration	Black	NICE TA 155, not recommended for the treatment of wet age-related macular degeneration
Pegfilgrastim	Recombinant human granulocyte-colony stimulating factor (G-CSF) - neutropenia	Red	
Peginterferon	Histologically proved hepatitis C	Red	As per NICE
Pegvisomant (Somavert)	Acromegaly who have had an inadequate response to surgery and/or radiation therapy	Black	Refer to NHSE commissioning position
Pemetrexed	Cancer	Red	Also refer to Cancer Drugs Fund. Any prescribing supported by NHS England will be prescribed by the specialist.
Pembrolizumab	untreated PD-L1-positive metastatic non-small-cell lung cancer	Red	July 2017 MCC - NHSE commissioned
Penicillamine	Cystinuria	Amber - shared care	March 2016 MCC - First Line, Existing evidence based treatment
Penicillamine	Rheumatoid arthritis	Amber - specialist initiation	Suitable for a GP to continue, with appropriate supporting documents. No written shared care agreement necessary.
Pentosan polysulfate (Elmiron)	Interstitial cystitis	Red	Updated Aug 2015 - York Trust updated historic position- now red on formulary.
Pentoxifyline (Trental)	Peripheral vascular disease	Black	NICE TA 223 Peripheral arterial disease
Peptac	First choice product for the symptomatic relief of heartburn, reflux oesophagitis, hiatus hernia and dyspepsia due to reflux.	Green	Jan 2017 MCC - Gaviscon Advance to remain as an alternative choice.
Perampanel (Fycompa®)	Epilepsy	Amber - specialist initiation	Formulary review - Specialist initiation and supply for initial three months with treatment as per treatment care plan
Pergloticase		Black	NICE TA 291. Pegloticase is not recommended within its marketing authorisation
Pergolide	Parkinsons Disease	Amber - specialist recommendation	June 2017 MCC - Confirmation of commissioning position
Pertuzumab	Cancer	Red	
Phosphate enema	Constipation	Green	April 2016 MCC - Confirmation of formulary status
Pimecrolimus (topical)	Atopic dermatitis (eczema)	Green	
Pimozide	Antipsychotic	Red	
Pirfenidone	Idiopathic pulmonary fibrosis	Red	NICE TA 282 as per NHS England commissioning policies
Plerixafor	Stem cell mobilisation prior to autologous transplantation	Red	Subject to NHS England commissioning policies
Pomalidomide	Cancer - haematology Treatment of relapsed and refractory multiple myeloma	Black	April/ May 2016 MCC - NICE TA338 not approved by NICE
Ponatinib	Cancer	Red	July 2017 MCC - NHSE commissioned
Posaconazole	Pulmonary aspergillosis	Red	Subject to NHS England commissioning policies
Potassium ascorbate eye drops (unlicensed)	All indications	Red	June 2017 MCC
POWERBreathe Medic		Grey	Not expected to be routinely commissioned
Pramipexole	Parkinsons Disease	Amber - specialist recommendation	June 2017 MCC - Confirmation of commissioning position
Prasugrel	Percutaneous coronary intervention for treating acute coronary syndromes	Amber - specialist initiation	As per NICE TA 317. Discharge letter expected to include a stop date
Praziquantal	For the treatment of protozoal infections	Amber	March 2016 MCC - Confirmation of formulary status
Prednisolone rectal	Ulcerative colitis and other rectal / GI conditions	Amber - specialist recommendation	April 2016 MCC - Confirmation of formulary status
Preservision	Antioxidants for ocular health	Black	Not listed as ACBS, inherited NYYPCT policy, CCG policy in development
Primidone	Epilepsy	Amber	Formulary review – for continuation of existing patients only
Procarbazine	Cancer	Red	
Procyklidine Hydrochloride	Parkinsons Disease	Amber - specialist recommendation	June 2017 MCC - Confirmation of commissioning position
Pro-D3	Vitamin D for deficiency & insufficiency	Black	Feb 16 MCC See Oral Vit D Medal Ranking
Promixin (inhaled colistimethate)	Non CF bronchiectasis	Black	Lack of robust clinical and cost effectiveness to support its use.
Propantheline	Urinary incontinence	Black	Not routinely commissioned, as per NICE guidance (CG40)
Propylthiouracil	Hyperthyroidism	Green	April 2016 MCC - Confirmation of formulary status
Prostaglandin analogues eye drops e.g. latanoprost	Ocular hypertension	Green	First line: Generic latanoprost 0.005% 2nd line: Bimatoprost or travaprost For patients unable to have products containing preservatives 1st line: Latanoprost 50 micrograms/ml p/f eye drops (Monopost) UDV
Prucalopride	Chronic constipation in men	Black	Not approved following Sept 15 MCC - Clinical evidence does not support use in men.
	Chronic constipation in women only (as per product license)	Amber - specialist initiation	Requires specialist assessment for initiation. GPs may continue the prescribing when a review after a month's therapy demonstrates benefit.
Qlaira (estradiol + dienogest)	Contraception	Black	Unproven benefit over other COCs, inherited NYYPCT policy.

Quetiapine	Schizophrenia	Amber - specialist initiation	August 2015 - Biquelle® XL The CCG preferred choice where quetiapine XL (Seroquel XL) is prescribed.
QV cream	Creams/Gels for everyday use, frequent application.	Green - Third line after Epimax	April 2016 MCC - See Emollient Medal Ranking
QV Gentle wash	Gel/Washes/Soap substitute	Black	April 2016 MCC - See Emollient Medal Ranking
QV Bath Oil	Bath oil / additives	Green - third line	April 2016 MCC - See Emollient Medal Ranking
Rabies vaccine	Travel	Black	Not available at NHS expense, with the exception of patients whose occupation puts them at high risk of exposure e.g. people working in quarantine facilities, customs and excise officers
Racecadotril	Symptomatic treatment of acute diarrhoea	Black	Inadequate evidence to support use in patients likely to be encountered in UK primary care
Ranibizumab	Licensed indications	Red	Commissioned in accordance with NICE guidance for ARMD, DMO, RVO
Ranolazine	Symptomatic treatment of stable angina pectoris	Amber	For use as per NICE guidance (CG126)
Rasagiline	Parkinson's Disease	Amber - specialist recommendation	For use as per NICE guidance (CG035)
Rasburicase	Hyperuricaemia	Red	Refer to local formulary
Regorafenib	Cancer	Red	
Resource ThickenUp Clear® powder	dysphagia	Green	Sept 2017 MCC
RESPeRATE	Hypertension (biofeedback)	Black	Device used to lower BP by changing breathing rates
Retapamulin 1% ointment	Skin infections such as impetigo	Black	
Retigabine	Epilepsy	Amber - shared care	Commissioned for use in accordance with NICE TA 232
Ribavirin	Hepatitis C in combination with interferon	Red	
Rifaximin (Targaxan®)	Preventing episodes of overt hepatic encephalopathy in adults	Amber - specialist initiation	NICE TA 337 recommends as a treatment option. (MCC April 2015)
Rifaximin	Traveller's diarrhoea	Grey	Antimicrobial choices routinely will follow the primary care antimicrobial guidance
Rifaximin	Pouchitis	Red	
Riluzole	Amyotrophic lateral sclerosis	Amber - shared care	
Riociguat (Adempas)	Chronic thromboembolic pulmonary hypertension	Red	Updated following August 2015 MCC
Risedronate	Osteoporosis	Green	See medal ranking for CCG choices http://www.valeofyorkccg.nhs.uk/rss/data/uploads/prescribing/medal-ranked-drugs/medal-ranking-oral-bisphosphonates-voyccg-march-2015.pdf
Risperidone	Schizophrenia	Amber - shared care	http://nww.lhp.leedsth.nhs.uk/common/guidelines/detail.aspx?id=616
Risperidone depot injection	Schizophrenia	Amber - specialist initiation	May 2017 MCC
Rituximab	Licensed indications NICE approved and CCG commissioned	Red	March 2015 MCC - Approved as a 2nd line option for the treatment of warm AIHA in adults with relapsing disease/refractory to corticosteroids. Rituximab is recommended as a 1st line in cold AIHA. Not for GP prescribing.
Rivaroxaban (Xarelto®)	Prevention of VTE after total hip/knee replacement	Red	Supply to be provided upon discharge
	Acute coronary syndrome	Amber - specialist recommendation	NICE TA 335 recommends as a treatment option. (MCC April 2015)
	Treatment of DVT	Green	Refer to treatment pathway
	Stroke prevention in AF	Green	Refer to care pathway and GP decision aid
Rivastigmine	Alzheimer's disease	Amber - specialist initiation	Updated position from Leeds & York Mental Health Trust January 2015. For use as per NICE guidance
Roflumilast	COPD	Amber - specialist initiation	August 2017 MCC in line with NICE TA461
Romiplostim	ITP	Red	TA 221- recommended for specified people with chronic, sever and refractory ITP
Ropinirole XL	Parkinson's Disease	Amber - specialist recommendation	Ropinirole XL is not as cost effective as immediate release ropinirole at all doses, its use is restricted to instances for example where symptom control is problematic. Eppinix® XL or Repinex® XL are the modified release brands of choice MCC August 2015.
Rosuvastatin	Lipid lowering	Green	Refer to Vale of York guidance
Rotigotine	Parkinson's Disease	Amber - specialist recommendation	Expected to be commissioned as an option for patients who are unable to take oral dopamine agonists. Suitable for prescribing in primary care following specialist initiation and stabilisation.
Rufinamide	Epilepsy	Amber - specialist initiation	Specialist initiation and supply with treatment as per the care plan.
Ruxolitinib tablets (Jakavi®)	Cancer - haematology	Red	Refer to Cancer Drugs Fund. Any prescribing supported by NHS England will be prescribed by the specialist
	Polycythaemia vera	Black	November 2015 MCC
Sacubitril/Valsartan (Entresto)	Treatment of symptomatic chronic heart failure	Amber - specialist initiation	June 2016 MCC - As an option for treating symptomatic chronic heart failure with reduced ejection fraction as per NICE
Safinamide	Treatment of adult patients with idiopathic Parkinson's disease (PD) as add-on therapy to a stable dose of Levodopa	Amber - specialist recommendation	Feb 2017 MCC
Salmeterol 25mcg generic MDI inhaler	COPD	Green	June 2015 MCC. Continuation in existing patients only. Not listed on the Vale of York CCG COPD pathway.
Salmeterol 50mcg (Serevent accuhaler®)	COPD	Green	June 2015 MCC. Continuation in existing patients only. Not listed on the COPD pathway.
Sapropterin (Kuvan®)	Phenylketonuria	Black	NHS England position - not for GP prescribing, updated following MCC August 2015.

Sastravi® (multiple strengths) Combination of carbidopa/levodopa/entacapone)	Parkinson's disease as per product license.	Amber - specialist recommendation	July 2016 MCC - Offers better value than the reference product Stalevo®
Sativex (Cannabis spray)	Symptoms of multiple sclerosis	Black	This should not be prescribed in primary care for any indication.
Saxagliptin (saxagliptin + metformin)		To confirm	
Secukinumab s/c injection (Cosentyx®)	Moderate to severe plaque psoriasis	Red	MCC August 2015 approved in line with NICE TA 350.
Secukinumab	for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors	Red	Oct 2016 MCC - in line with NICE TA 407
secukinumab	treating active psoriatic arthritis after inadequate response to DMARDs	Red	June 2017 MCC
Selegiline Hydrochloride	Parkinsons Disease	Amber - specialist recommendation	June 2017 MCC - Conformation of commissioning position
Sertindole	Schizophrenia	Red	
Sevelamer	phosphate binding	Red	Sept 2017 MCC
Shingles vaccine - see Zostavax	See Zostavax		
Sildenafil	Erectile dysfunction	Green	Refer to CCG medal ranking guidance
Sildenafil chewable tablet (Nipatra®)	Erectile dysfunction	Black	Generic sildenafil tablets are the agent of choice.
Sildenafil	Pulmonary hypertension, digital ulceration in systemic sclerosis	Red	Commissioned by NHS England from specialist centres only. Not for GP prescribing for these indications.
Sildenafil	Ischaemia	Red	
Sildenafil	Management of priapism - As per formulary statement	Amber - specialist recommendation	March 2016 MCC - Confirmation of formulary status
Silk garments	Eczema/allergic skin conditions	Black	Ratified following November 2014 MCC. Not commissioned for existing or new patients.
Sitagliptin	Diabetes mellitus	Green	Combined tablet with metformin (Janumet®) is non-formulary
Sirolimus	Immunosuppression - organ transplantation	Amber - shared care	
Slow sodium	For the management of low sodium levels	Green	March 2016 MCC - Confirmation of formulary status
Sodium aurothiomalate	Rheumatoid arthritis	Amber - shared care	Shared care for the indications listed in the guideline only
Sodium Chloride Hypertonic	Use in patients aged six years of age and over with a respiratory condition leading to retained bronchopulmonary secretions	Amber - specialist initiation SCG	Oct 2016 MCC - Approved where usual treatment (physiotherapy airway clearance, adequate systemic hydration, dornase alpha for those with CF, carbocysteine where indicated) isn't sufficiently effective. Following SCG
Sodium chloride oral solution 1 mmol/ml	Sodium supplementation/ replacement in neonates	Amber - specialist recommendation	April 2016 MCC - Confirmation of formulary status
Sodium chloride 5%, sodium hyaluronate 0.15% preservative-free eye drops (ODM5)	Corneal oedema/Fuchs' endothelial dystrophy	Amber - specialist recommendation	March 2016 MCC - Cost effective preparation
Sodium citrate enema	Constipation	Green	April 2016 MCC - Confirmation of formulary status
Sodium cromoglycate 2% eye drops	Hayfever & allergic rhinitis	Green	Ratified following MCC Feb 15. Refer to Vale of York CCG medal rankings for hayfever & allergic rhinitis formulary choices http://www.valeofyorkccg.nhs.uk/rss/index.php?id=medal-ranked-drugs
Sodium fusidate (oral formulations)	Infections	Amber - specialist recommendation	March 2016 MCC - Confirmation of formulary status
Sodium oxybate	Narcolepsy with cataplexy	Black	Inherited NYYPCT policy (under review)
Sodium phenylbutyrate		Red	
Soffen cream	Creams/Gels for everyday use, frequent application.	Green - Second line after Epimax	April 2016 MCC - See Emollient Medal Ranking
Solifenacin	Urinary incontinence	Green	See priority list for antimuscarinic choices in AOB
Solifenacin and tamsulosin combination (Vesomni)	Storage and voiding symptoms associated with benign prostatic hyperplasia	Black	Single agents already formulary items and combination product does not offer advantages to health economy when taking in to account patent expiries of solifenacin
Somatropin	Growth hormone deficiency	Amber - shared care	For use as per NICE guidance (TA064,TA042)
Sorafenib	Cancer	Red	
Sorafenib	advanced hepatocellular carcinoma	Red	MCC October 2017
Specials	Unlicensed formulations	Grey	Seek best value advice on specials from Medicines Management Pharmacist
Staneke® (multiple strengths) Combination of carbidopa/levodopa/entacapone)	Parkinson's disease as per product license.	Amber - specialist recommendation	July 2016 MCC - Offers better value than the reference product Stalevo®
Stexerol D3 25000 IU Tabs	Vitamin D for deficiency & for insufficiency & for replete	Green	Feb 16 MCC First Line Option - See Oral Vit D Medal Ranking
Stexerol D3 1000iu tabs	Vitamin D for insufficiency	Green	Feb 16 MCC Second Line Option - See Oral Vit D Medal Ranking
Stiripentol	Epilepsy (unlicensed)	Amber - Specialist initiation	GP continuation following initiation by a Specialist Consultant for the treatment of Dravet Syndrome

St Johns Wort	Depression	Black	Not routinely commissioned, as per NICE guidance (CG091,CG090,CG028)
Strontium ranelate (Protelos®)	Osteoporosis	Amber - Specialist initiation	See medal ranking for CCG choices http://www.valeofyorkccg.nhs.uk/rss/data/uploads/prescribing/medal-ranked-drugs/medal-ranking-oral-bisphosphonates-voyccg-march-2015.pdf
Suboxone 2mg and 8mg	Opioid dependence	Green	May 2017 MCC Must be prescribed in conjunction with substance misuse service recovery co-ordinator and prescribed generically
Sucalfate enema (unlicensed)	Treatment of late/chronic radiation induced proctitis	Red	*updated following February 2015 MMC* Hospital use only when no other viable treatment options. Requirement for its use is rare.
Sulfasalazine	Rheumatology and gastroenterology indications as listed in the SCG	Amber - shared care	Shared care for the indications listed in the guideline only
Sulphadiazine	Toxoplasmosis	Red	March 2016 MCC - Confirmation of formulary status
Sumatriptan	Migraine prophylaxis	Green	
Sunitinib	Cancer	Red	July 2017 MCC - NHSE commissioned
Systane balance	Evaporative dry eye	Amber - specialist recommendation	May 2016 MCC
Tacrolimus	Atopic dermatitis (eczema)	Green	
Tacrolimus	Immunosuppression - organ transplantation	Amber - shared care	
Tadalafil 10mg and 20mg tablets	Erectile dysfunction	Green	But refer to CCG medal ranking guidance
Tadalafil once daily formulation	Erectile dysfunction	Black	Refer to CCG medal ranking guidance
Tadalafil	Benign prostate hyperplasia	Black	No evidence that it is more effective than other formulary drugs for this clinical indication
Tadalafil	Management of priapism - As per formulary statement	Amber - specialist recommendation	March 2016 MCC - Confirmation of formulary status
Tamoxifen	Hereditary haemorrhagic telangiectasia	Red	NEW Sept 13
Tamoxifen	Breast cancer	Amber - specialist initiation	
Tapentadol prolonged released tablets (Palexia SR®)	Moderate to severe acute pain in adults	Amber - specialist initiation	Jan 16 MCC - As detailed in treatment pathway
Targinact (oxycodone + naloxone)	Severe pain	Green	(Ratified from December MMC) Individuals who have tried at least 2 other opioids and have intractable opioid induced constipation that has not responded to two full dose laxatives.
Tegafur/uracil	Chemotherapy	Red	
Teleprevir	Hepatitis C	Red	NICE TA 252 . Specialist drug for the treatment of hepatitis C. Telaprevir – recommended with peginterferon and ribavirin in compensated liver disease in untreated patients, or those unresponsive to previous interferon treatments.
Temazepam formulations	Insomnia	Refer to Vale of York CCG medal ranking guidance for 1st, 2nd and subsequent choice	Ratified following MCC February 2015. http://www.valeofyorkccg.nhs.uk/rss/index.php?id=medal-ranked-drugs
Temozolomide	Chemotherapy	Red	
Temsirolimus	Cancer	Red	
Tenofovir	Hepatitis B	Red	Local service provider Leeds
Teriparatide (Forsteo®)	Osteoporosis	Red	See medal ranking for CCG choices http://www.valeofyorkccg.nhs.uk/rss/data/uploads/prescribing/medal-ranked-drugs/medal-ranking-oral-bisphosphonates-voyccg-march-2015.pdf
Testosterone patch (Intrinsa)	Hypoactive sexual desire disorder (HSDD)	Amber - specialist initiation	Will be initiated by consultants specializing in the diagnosis and treatment of HSDD.
Thalidomide	Chemotherapy	Red	
Thorens 25000iu/2.5ml	Vitamin D for deficiency	Green	Feb 16 MCC Try to avoid Use 3rd line if needed - See Oral Vit D Medal Ranking
Thorens 10000iu (200iu/drop) 25000iu/2.5ml	Vitamin D for insufficiency & replete	Green	Feb 16 MCC First Line Option - See Oral Vit D Medal Ranking
Tiagabine	Epilepsy	Amber - specialist initiation	For use as per NICE guidance (CG137)
Ticagrelor	Acute coronary syndrome	Amber - specialist initiation	Commissioned only in accordance with NICE TA236 for treatment up to 12 months after AC, cardiologist initiation only (discharge to include stop date) Updated following MCC April 2015
Ticagrelor	In combination with aspirin, for preventing atherothrombotic events after myocardial infarction.	Amber - specialist initiation	Feb 2017 MCC - In accordance with NICE TA 420 for treatment to stop when clinically indicated or at a maximum of 3 years.
Tick-borne encephalitis vaccine	Travel	Black	To be recommended by consultant microbiologist only - July 16 MCC
Timolol 0.5% eye drops	Glaucoma	Black	August 2017 MCC
Tiopronin (Unlicensed)	Cystinuria	Red - Hospital Only	March 2016 MCC - Second line (unlicensed treatment)
Tiotropium Respimat	Bronchiectasis	Amber - specialist initiation	August 2016 MCC - When LAMA required and patient is unable to use a dry powder inhaler.
Tiotropium 2.5 microgram inhaler (Spiriva Respimat®)	Asthma	Green	MCC Apr 2017 - Only as per updated asthma treatment pathway - for high dose therapies "consider the addition of a 4th drug"
Tiotropium and Oldaterol (Spiolto Respimat®)	COPD	Green	MCC October 2017 - crification of commissioning position
TNF-alpha inhibitors	Ankylosing spondylitis and non-radiographic axial spondyloarthritis	Red	March 2016 MCC - As per NICE TA383

Tobramycin dry powder inhaler 28mg/capsule (TOBI)	Cystic fibrosis	Red	Recommendations in accordance with NICE and NHS England policies
Tobramycin nebuliser solution (Tobi®, Bramitob®)	Bronchiectasis	Red	MCC May 2015 - Hospital specialist only until the pathway is formally reviewed at MCC.
Tobramycin nebulised	Cystic fibrosis (new requests York hospital)	Red	Agreed CF specialists at York Trust only will retain prescribing responsibility for any new requests in lieu of proposed repatriation of these drugs to CF specialist centres
Tobramycin nebulised	Cystic fibrosis (new requests Leeds or any patients already established in primary care York/Leeds hospital)	Amber - shared care	Commissioned in accordance with NHS England policies
Tocilizumab IV and subcutaneous injection (RoActemra®)	Rheumatoid arthritis	Red	Treatment option for rheumatoid arthritis patients in line with NICE TA 247. (MCC April 2015)
Tocilizumab	In combination with methotrexate, is recommended as option for treating rheumatoid arthritis, and can be used as monotherapy for people who cannot take methotrexate because it is contraindicated or because of intolerance.	Red – Specialist prescribing only	Feb 16 MCC - Approved in line with NICE TA375
Tocilizumab	RA/JIA	Red	
Tolcapone	Parkinson's Disease	Red	
Tolvaptan	Hyponatraemia and other endocrine uses	Black	Subject to NHS England commissioning policies
Tolvaptan (Jinarc®)	Autosomal dominant polycystic kidney disease	Red	Dec 15 MCC - Specialist use only, as per NICE criteria.
Tolterodine	AOB	Green	Refer to CCG local priority list for AOB. MCC August 2015 Neditol® XL capsules is the preferred brand when tolterodine XL is indicated.
Toothpastes e.g. Duraphat or fluoride preparations and mouthwashes	when GPs requested to prescribe by a dentist	Black	Dec 15 MCC – GPs should not accept requests to prescribe medicines that a dentist could reasonably prescribe themselves.
Topiramate	Epilepsy	Amber - specialist initiation	
Topiramate	Weight loss	Grey	Negative opinion on support of product license, non formulary. Do not prescribe for this indication.
Trastuzumab	Cancer	Red	Specialist use only as per NICE/NHS England commissioning policies
Trastuzumab emtansine	treating HER2-positive advanced breast cancer after trastuzumab and a taxane	Red	August 2017 MCC
Triamcinolone nasal spray	Hayfever & allergic rhinitis	Green	Ratified following MCC Feb 15. Refer to Vale of York CCG medal rankings for hayfever & allergic rhinitis formulary choices http://www.valeofyorkccg.nhs.uk/rss/index.php?id=medal-ranked-drugs
Trihexyphenidyl Hydrochloride	Parkinsons Disease	Amber - specialist recommendation	June 2017 MCC - Conformation of commissioning position
Trimetazidine	Severe coronary artery disease (unlicensed)	Grey	
Triptorelin	Prostate cancer	Amber - specialist recommendation	
Triptorelin	precocious puberty	Amber - specialist initiation	Nov 2016 MCC
Tropicamide eye drops	Pupil dilation	Green	August 2016 MCC - Confirmation of formulary position
Trospium	AOB	Green	Refer to CCG clinical guidance for management of AOB
Typhoid vaccine (oral)	Travel	Black	Should be prescribed on a private basis - National policy
Ubiquinone/ubidecarenone (coenzyme Q10)	Prevention of statin-induced myotoxicity (unlicensed)	Grey	No recommendation for use by National Advisory Committee on Borderline Substances. Not expected to be routinely commissioned
Ulipristal Acetate (Esmya)	intermittent treatment of symptomatic uterine fibroids.	Amber - specialist initiation	June 2017 MCC
Ulipristal Acetate (Esmya)	pre-operative treatment of fibroids.	Black	June 2017 MCC
Ulipristal Acetate (EllaOne)	Emergency contraception	Green	levonorgestrel first line, ulipristal a treatment option 72-120 hours after coitus
Ultrabase cream	Creams/Gels for everyday use, frequent application.	Green - Second line after Epimax	April 2016 MCC - See Emollient Medal Ranking
Unguentum M cream	Creams/Gels for everyday use, frequent application.	Black	April 2016 MCC - See Emollient Medal Ranking
Ursodeoxycholic acid	Itching and stones	Amber - specialist recommendation	April 2016 MCC - Confirmation of formulary status
Ustekinumab (Stelara®) s/c injection	Psoriasis/psoriatic arthritis	Red	June 2015 MCC - approved in line with NICE TA 340
Ustekinumab	plaque psoriasis in children and young people	Red	August 2017 MCC
Ustekinumab	moderately to severely active Crohn's disease after previous treatment	Red	August 2017 MCC
Vacuum pump devices	Erectile dysfunction	Amber - specialist recommendation	September 2015 MCC - refer to Vale of York CCG RSS guidance for erectile dysfunction
Valganciclovir	Prevention of CMV disease following solid organ transplantation	Red	
Valganciclovir	Induction and maintenance treatment of cytomegalovirus retinitis in patients with AIDS	Red	
Valproic acid	Epilepsy	Black	Formulary review - Epilepsy specialists for adult/children services advice.

Sodium Valproate/Valproic acid (Depakote tablets®, liquid ®)	Bipolar effective disorder		See Leeds & York mental health trust position, psychiatry use only.
Vancomycin	Treatment of C. difficile infection	Amber - specialist recommendation	To be recommended by consultant microbiologist only - July 16 MCC
Vandetinib	Cancer	Red	Refer to Cancer Drugs Fund. Any prescribing supported by NHS England will be prescribed by the specialist.
Vardenafil (plain and orodispersible tablets)	Erectile dysfunction	Green	But refer to CCG medal ranking guidance
Varenicline	Smoking cessation	Green	For use as per NICE guidance (PH010,PH005,PH001,TA123). Should normally be prescribed only as part of a programme of behavioural support i.e. patient should be under the care of a Registered Smoking Cessation Advisor or the Specialist Stop Smoking commissioning
Vedolizumab (Entyvio®)	Crohn's Disease	Red	Approved following MCC Sept 2015 for use in accordance with NICE TA352
Vedolizumab (Entyvio®) IV infusion	Ulcerative colitis	Red	June 2015 MCC - approved in line with NICE TA 342
Vemurafenib	Cancer	Red	
Venlafaxine (dose less than 300mg)	Depression	Green	refer to Leeds and York Mental health Partnership
Venlafaxine (dose 300mg or more)	Depression	Amber - shared care	http://www.lhp.leedsth.nhs.uk/common/guidelines/detail.aspx?id=705
Verapamil	Arrhythmias	Amber - specialist recommendation	April 2016 MCC - Confirmation of formulary status
Verteporfin (Visudyne®) photodynamic therapy	Treatment of central serous chorioretinopathy (CSCR)	Black	March 2016 MCC - Lack of clinical evidence to support
Vesomni - see solifenacin/tamsulosin	See solifenacin/tamsulosin combination		
VIBRO-PULSE®		Grey	If commissioned, expected that Tissue Viability Nurse involvement will be a requirement
Vildagliptin (and vildagliptin+metformin)	Diabetes mellitus	Black	
Vimovo (naproxen + esomeprazole)	Symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis	Black	Inherited NYPCT policy (under review)
Vinblastine	Cancer	Red	
Vincristine	Cancer	Red	
Vinorelbine	Cancer	Red	All formulations
Vinflunine	Cancer	Black	NICE TA 272 negative for urothelial tract carcinoma
Vinorelbine	Cancer	Red	
Visionace	Antioxidants for ocular health	Black	Not listed as ACBS, inherited NYPCT policy, CCG policy in development
Vismodegib	Cancer	Red	Refer to Cancer Drugs Fund. Any prescribing supported by NHS England will be prescribed by the specialist.
Vitamin B Compound strong tablets	Re-feeding syndrome	Amber - specialist initiation	Approved following Sept 15 MCC. Uses supported by NICE CG 32 and local clinicians indicate some patients may require use beyond the initial 10 day period.
Vitamin B Compound strong tablets	Alcohol detoxification	Black	June 2015 MCC. NICE guidance only recommends for re-feeding syndrome. TEVV and Leeds York mental health no longer routinely recommend this product.
Vitamins (ocular health)	Age related macular degeneration	Black	Updated position June 2014 Medicines Commissioning Committee
Vitalux	Antioxidants for ocular health	Black	Not listed as ACBS, inherited NYPCT policy, CCG policy in development
Vita-Pos ointment	Dry eye	Green	May 2016 MCC - Preservative-free Option. Ointments usually for night time use
Viteyes	Antioxidants for ocular health	Black	Not listed as ACBS, inherited NYPCT policy, CCG policy in development
Viteyes II formula	Antioxidants for ocular health	Black	Not recommended for prescribing at NHS cost. Where specialists recommend these dietary supplements to patients, must advise there are purchased over the counter
Voriconazole	Pulmonary aspergillosis	Red	As per NHS England policies
Vortioxetine	Treatment of major depressive episodes in adults	Amber - consultant initiation	For depression that has not responded to two other antidepressants as per NICE TA. January 2016 MCC
VSL#3	Co-administration with antibiotics for prophylaxis of C difficile infection in over 65 year olds	Black	VSL#3 Co-administration with antibiotics for prophylaxis of C difficile infection in over 65 year olds Red December 2015 – Trust have suspended the strategy as routine prescribing of VSL does not appear to have had any effect C. difficile rates. Reviewed at MCC January 2016 - No longer approved due to apparent lack of effectiveness.
VSL#3	Pouchitis (Drug Tariff borderline substance)	Green	Only as per Drug Tariff recommendation, should not be prescribed for other indications
XAILIN GEL 10g Pres free	Mild dry eye	Green	May 2016 MCC - Preservative-free Option
XAILIN FRESH single use pres free	Mild dry eye	Green	May 2016 MCC - Preservative-free Option
XAILIN Night ointment	Dry eye	Green	May 2016 MCC - Preservative-free Option. Ointments usually for night time use
Yasmin	Contraception	Green - Third line Option after Gedarel	April 2016 MCC - 3rd line after cheaper branded generics (Gedarel 1st line)
Yasmin (or branded generic equivalents)	Acne	Black	March 2016 MCC - Not cost effective
Yellow fever vaccine	Travel	Black	Should be prescribed on a private basis - National policy

Yohimbine	Erectile dysfunction	Grey	Not expected to be routinely commissioned. There is a lack of robust and comparative efficacy data, lack of robust safety data, absence of a licensed source of Yohimbine and potential increased cost of treatment compared to established licensed treatments. British Society for Sexual Medicine recommends against use.
Zanamavir	For use when influenza virus circulating - As per NICE guidance	Green	March 2016 MCC - Confirmation of formulary status
ZerAQS Cream	Gel/Washes/Soap substitute	Black	April 2016 MCC - See Emollient Medal Ranking
Zerocream	Creams/Gels for everyday use, frequent application.	Green - First line	April 2016 MCC - See Emollient Medal Ranking
Zeroderm Ointment	Greasy/ Very Greasy Ointments for very dry skin and/or acute flares.	Green - Second line after Emuls Oint	April 2016 MCC - See Emollient Medal Ranking
Zerodouble	Creams/Gels for everyday use, frequent application.	Green - Second line after Epimax	April 2016 MCC - See Emollient Medal Ranking
Zerolatum Bath additive	Bath oil / additives	Black	April 2016 MCC - See Emollient Medal Ranking
Zeroneum Bath Oil	Bath oil / additives	Green - second line	April 2016 MCC - See Emollient Medal Ranking
Ziconotide	Intrathecal analgesia	Black	Subject to NHS England commissioning policies August 2015. Not for prescribing in primary care.
Zoely (Nomegestrol/Estrodiol)	Combined oral contraception	Black	Significantly more expensive than other agents with insufficient evidence of clinical benefits over other alternatives.
Zoledronic acid	Reduction of bone damage in advanced malignancies involving bone	Red	
Zolendronic acid	Osteoporosis	Red	Sept 2017 MCC
Zonisamide	Epilepsy	Amber	Refer to the formulary http://www.yorkandscarboroughformulary.nhs.uk/chaptersSubDetails.asp?FormularySectionID=4&SubSectionRef=04.08.01&SubSectionID=A100
Zopiclone, zolpidem, zalaplon (z-drugs)	Insomnia	Refer to Vale of York CCG medal ranking guidance for 1st, 2nd and subsequent choice	Ratified following MCC February 2015. http://www.valeofyorkccg.nhs.uk/rss/index.php?id=medal-ranked-drugs
Zostavax	Prevention of shingles	Green	As per DH national vaccination campaign schedule
Zuclopenthixol decanoate depot	Schizophrenia	Amber - specialist initiation	May 2017 MCC
Zuclopenthixol acetate	Schizophrenia	Red	